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COMPUTATIONAL MODELING FOR IDENTIFICATION OF LOW-FREQUENCY 
SINGLE NUCLEOTIDE VARIANTS   
Reliable detection of low-frequency single nucleotide variants (SNVs) carries 
great significance in many applications. In cancer genetics, the frequencies of somatic 
variants from tumor biopsies tend to be low due to contamination with normal tissue and 
tumor heterogeneity. Circulating tumor DNA monitoring also faces the challenge of 
detecting low-frequency variants due to the small percentage of tumor DNA in blood. 
Moreover, in population genetics, although pooled sequencing is cost-effective 
compared with individual sequencing, pooling dilutes the signals of variants from any 
individual. Detection of low frequency variants is difficult and can be cofounded by 
multiple sources of errors, especially next-generation sequencing artifacts. Existing 
methods are limited in sensitivity and mainly focus on frequencies around 5%; most fail 
to consider differential, context-specific sequencing artifacts. To face this challenge, we 
developed a computational and experimental framework, RareVar, to reliably identify 
low-frequency SNVs from high-throughput sequencing data. For optimized performance, 
RareVar utilized a supervised learning framework to model artifacts originated from 
different components of a specific sequencing pipeline. This is enabled by a customized, 
comprehensive benchmark data enriched with known low-frequency SNVs from the 
sequencing pipeline of interest. Genomic-context-specific sequencing error model was 
trained on the benchmark data to characterize the systematic sequencing artifacts, to 
derive the position-specific detection limit for sensitive low-frequency SNV detection. 
Further, a machine-learning algorithm utilized sequencing quality features to refine SNV 
candidates for higher specificity. RareVar outperformed existing approaches, especially 
vi 
at 0.5% to 5% frequency. We further explored the influence of statistical modeling on 
position specific error modeling and showed zero-inflated negative binomial as the best-
performed statistical distribution. When replicating analyses on an Illumina MiSeq 
benchmark dataset, our method seamlessly adapted to technologies with different 
biochemistries. RareVar enables sensitive detection of low-frequency SNVs across 
different sequencing platforms and will facilitate research and clinical applications such 
as pooled sequencing, cancer early detection, prognostic assessment, metastatic 
monitoring, and relapses or acquired resistance identification. 
 
Yunlong Liu, Ph.D., Chair 
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Chapter 1. Introduction and Literature Review 
1.1 Importance of Low Frequency SNVs in Biomedical Research and Applications 
Single nucleotide variants (SNVs) are the most common type of variation [1, 2], 
and are also currently the major data source to derive drug targets and biomarkers [3].  
Thus identifying SNVs and studying the function of SNVs constitute key aspects in the 
realm of genomics and genetics. Previous studies in cancer as well as population 
genetics have reported great successes in identifying disease susceptibility genes via 
germline SNVs [4-11] and common SNPs [12, 13]. Yet with the accumulation of 
knowledge on the impacts of mutations on disease predisposition, disease etiology[14] 
as well as the development of new clinical applications, there is a clear demand for 
identifying and analyzing low frequency SNVs in basic biological research and clinical 
applications [15-19]. 
 
1.1.1 Low Frequency SNVs in Cancer Research and Clinical Applications 
In cancer research, a widely accepted notion is that cancer is a complex disease 
arising from sequentially accumulation of somatic mutations, which leads to the 
transformation of normal cells to cancer cells [20, 21]. Thus somatic mutations are the 
key for us to understand carcinogenesis and also seek proper treatments. However, 
identifying somatic mutations from tumor samples is more challenging than germline 
mutation detection using purified peripheral blood. The first reason is the lower 
frequencies of these somatic mutations since tumor samples from biopsies are often of 
low purity. The low purity is the result of normal cells contamination [22, 23], as well as 
the highly heterogeneous nature of the tumor cells, which are a mixture of multiple 
genetically different tumor subpopulations [24, 25]. Previous work summarized the 
estimated tumor purity from existing major cancer studies, in which lung cancer has a 
large number of samples with purity between 20% and 40% and the purity for some 
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samples are even less than 20% [22]. Different levels of heterogeneity are observed in 
tumor. The Intratumor and the intercellular genetic heterogeneity are the main sources of 
complication for identification of low frequency mutations. In addition, the tumor samples 
may have lower quality. An increased background mutation rate is expected for cancer 
biopsy specimens that are formalin-fixed and paraffin-embedded (FFPE) due to cross-
linking [26, 27]. Thus, efficiently distinguishing low frequency somatic mutations from 
background errors carries great significance in cancer research. It is also important in 
clinical applications, since it enables the early diagnosis, cancer progression monitoring 
and relapse identification, which are essential components of cancer treatment.  
Besides, low frequency mutation detection is also desirable in newly developed 
applications. The recent discovery of circulating tumor DNA (ctDNA) gained much 
attention from cancer researchers and clinicians since contrast to traditional tumor 
biopsy, which is invasive and can only offer a snapshot of the tumor genetics landscape 
at certain checkpoints, ctDNA based ‘liquid biopsy’ [28] is non-invasive and can be done 
repeatedly for close monitoring of early sign of relapse or metastasis [29-32]. However, 
ctDNA only represents a small percentage of all blood sample DNA [33]. A previous 
research [34] reported for some advanced cancers, ctDNA is about 1~10% of blood 
DNA. 
 
1.1.2 Low Frequency SNVs in Population-Genetics Research 
Single nucleotide polymorphism (SNP) is an SNV occurring within at least 1% a 
population [35]. Information about polymorphic positions in the genome and the analyses 
on frequencies of variant alleles in various populations are the key inquiries of population 
genetics. To increase the power of population genetic studies, estimating allele 
frequencies from a large number of population samples is desirable due to higher 
accuracy. Individually sequencing a large number of samples is usually cost-prohibitive, 
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thus sequencing pooled DNA samples [36-38] as a cost-effective alternative was 
developed and also proved to generate more accurate allele frequency estimations [39-
41] than individual sequencing at similar cost. However, pooling larger number of 
individuals also brings the challenge of distinguishing sequencing errors from low 
frequency alleles. Further, with the paradigm shift in complex diseases studies from 
‘common disease-common variants’ (CDCV) to ‘common disease-rare variants’ (CDRV) 
[42-44], the importance of reliably identifying low frequency (0.5~5% minor allele 
frequency or MAF) to rare (MAF < 0.5%) variants is again pinpointed. 
 
1.2 NGS Protocols, Applications and Limitations 
Determining the sequence composition is a fundamental task in biomedical 
researches. To determine the sequence of base pairs that make up human DNA, the 
Human Genome Project was launched in 1990 and took $3 billion and 13 years to 
complete. The monumental project was accomplished with Sanger sequencing, which is 
considered the first generation sequencing technology. Despite many technical 
improvements made to the technology, after dominating the sequencing industry for 
more than two decades, Sanger sequencing could not keep pace with the great demand 
for cheaper, faster and more accurate sequencing of a large number of human 
genomes. This demand catalyzed the development of next-generation sequencing 
(NGS), which performs massively parallel sequencing and allows the entire human
4 
 genome to be sequenced within days. The much-improved sequencing technology 
revolutionized genomics and genetics researches and applications. To fully utilize its 
power, a clear understanding of its design and basic principles, as well as its power and 
limitations is indispensible. This is the key for low frequency SNV detection, since the 
task requires sensitively and specifically distinguishing true SNVs with close to 
sequencing error rate frequency from sequencing artifacts. In this section, the NGS DNA 
sequencing protocols are first introduced, then sequencing read alignment methods and 
complications are briefly introduced. The error sources of NGS platforms are 
summarized and the efforts trying to mitigate the problem are also introduced.  
 
1.2.1 NGS DNA Sequencing Experimental Protocols  
Since the release of the first NGS sequencer by 454 Life Science, during the past 
decade, many NGS platforms based on different technical protocols have been 
developed and released. Among those platforms, the leading benchtop sequencers for 
targeted gene panel or small genome sequencing are Illumina MiSeq, Ion PGM and Ion 
Proton. While the leading population- and production-scale sequencers designed for 
large number of whole genome, exome or transcriptome sequencing are Illumina HiSeq 
series.  
Taking Illumina sequencer as an example, a DNA sequencing experiment 
includes the following steps [45]: 
1. Library Preparation – for whole genome sequencing, the genomic 
DNA sample is randomly fragmented by sonication or nebulization, 
followed by 5’ and 3’ adapter ligation. Adapter-ligated fragments are 
PCR amplified and gel purified. For amplicon-based targeted 
sequencing, custom amplicon probes hybridize to flaking regions of 
interest in unfragmented genomic DNA to capture the desired 
sequences. Then PCR adds sequencing adapters to the amplicons 
and the amplicon library is ready for amplification. 
2. Library Amplification – The sequencing library is loaded in to a 
flowcell.  Adapter-ligated DNA fragments are separated into single 
strands. The surface of the flowcell is bounded by millions of oligos 
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complimentary to the library adapters, thus the single stranded library 
fragments are captured. Then each captured fragment is amplified 
into a clonal cluster via bridge amplification. 
3. Sequencing – Illumina uses sequencing-by-synthesis (SBS) 
technology. At each cycle, 4 types of fluorescently labeled nucleotides 
are added, the ones complementary to the template DNA are added 
and the emission from each cluster on the flowcell is recognized and 
recorded by the optical imaging system. The bases incorporated and 
the qualities are determined from the emission wavelength and 
intensity data. 
4. Data Analysis – Sequencing reads are aligned to a reference 
genome. Different variant calling algorithms can be applied on the 
aligned sequencing data. 
For Ion Torrent sequencers, a DNA sequencing experiment shares the above 4 
general steps but the technical details are different [46]. For library amplification, 
emulsion PCR is used. Adapter-ligated DNA fragments are separated into single strands 
and then are captured by beads under conditions favoring one template per bead. The 
DNA-bead complexes are then mixed with oil-aqueous emulsion to create individual 
droplets that encapsulate these DNA-bead complexes. These droplets are also called 
microreactors in which PCR amplification is performed. In the sequencing step, millions 
of beads flow across the Ion semiconductor chip, each depositing into a well. Then the 
chip is flooded with a sequence of the 4 nucleotides. Whenever a nucleotide 
incorporates a single stranded DNA, a hydrogen ion is released and changes the pH of 
the solution in the well. An ion sensitive layer beneath the well detects the change in pH 
and converts that to voltage and thus the base is detected. This technology is called Ion 
semiconductor sequencing.  
 
1.2.2 NGS Read Alignment 
NGS platforms generate large number of short reads. The majority of high-
throughput NGS platforms now can generate single or paired-end reads with 100 to 300 
in length, with Ion PGM system capable of generating millions of 400-base length reads. 
The relatively lower-throughput sequencer from 454 can generate reads up to 1000 
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nucleotides in length. In terms of throughput, Ion Torrent benchtop sequencer Ion PGM 
318 chip can generate 4-5.5 million reads while Ion Proton can generate 60-80 million 
reads. Illumina benchtop sequencer MiSeq can generate 25 million reads per run while 
population- and production-scale sequencer HiSeq series can generate 6 billion reads 
per run. 
Fast and accurately aligning enormous amount of short reads back to the 
reference genome is the key issue for NGS data analysis. To solve this problem, 
different strategies had been tested. From hashing the short reads [47-49], hashing the 
reference genome [50, 51] to Burrows-Wheeler transform (BWT) used by string 
matching theory, the speed, memory usage, error tolerance had been greatly improved. 
For Illumina sequencing data, BWT based Burrows-Wheeler aligner (BWA) [52] is the 
most widely used tool. For Ion Torrent data, TMAP from Torrent Suite Software is used 
since it optimized the modules and parameters to adapt to flexible read length. One 
major difficulty of read alignment is aligned reads from low-complexity reference genome 
regions. In addition, sequencing errors, including mismatches and micro-insertions and 
deletions (INDELs) can also complicate the alignment.  
 
1.2.3 NGS Error Profiles and Error Reduction Methods 
With the ever-increasing importance of NGS in genomics and genetics, the 
significance of accounting for experimental errors is also more prominent, especially in 
the application of identifying low frequency variants where the variant allele frequency 
could be close to or below sequencing error rate (0.1~1% for most platforms [53]). 
Starting from sample preparation, all steps can potentially generate errors [54]. In 
sample preparation step, nucleic acid degradation and FFPE crosslinking induced errors 
[55], as well as alien sequence contamination are the main sources. In library 
amplification step, PCR amplification errors [56] may be recognized as SNVs in the 
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subsequent SNV calling. During the sequencing step, all platforms show error profiles 
related to GC and/or AT content as well as homopolymers [57], and elevated error rates 
in low-complexity regions. In terms of the relationship between GC content and error rate 
of different platforms, Illumina and Complete Genomics platforms are more sensitive to 
GC content differences. For homopolymer length, except for Pacific Biosciences 
considered as ‘third generation sequencing’ technology [58], all the other platforms show 
elevated error rates when homopolymer length is larger than 10. Nevertheless, different 
platforms are more vulnerable to different types of errors due to the differences in the 
underlying technologies. Illumina and Ion Torrent sequencers are based on totally 
different sequencing biochemistries. For Illumina sequencers, substitution error is the 
major error source [59] and Nakamura et al. Identified sequence contexts that tend to 
trigger these errors [60]. Ion Torrent tends to have more indel errors around 
homopolymer sequences [61] and thus tends to generate false SNV calls due to 
erroneous alignment. 
To mitigate the NGS errors, many researchers have reported successes in 
reducing NGS errors by improved experimental protocols, especially the library 
preparation and amplification steps. “Barcoding” strategy has been discussed in several 
papers where a mutation is confirmed only if it appears in multiple read groups 
distinguishable by the barcodes [16, 62]. Circle sequencing improved the idea of 
independent mutation confirmation from multiple read groups by removing the need of 
adding barcodes [63]. Duplex sequencing approached the error reduction by requiring 
strand concordance on the mutations [18, 64]. However, most existing NGS data are 
generated from standard experimental protocols without the specially designed steps 
implemented in barcode, circle and duplex sequencing protocols described above, thus 
how to effectively distinguish sequencing artifacts and errors from low-frequency SNVs 
is an important topic in bioinformatics. In terms of bioinformatics approaches, many 
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researchers use filters, including requirements on sequencing read depth, base quality, 
mapping quality, strand bias, variant quality and mutation density [65]. Also, some 
researchers proposed using replicates [54] to reduce errors. SNVs are called from all 
replicates and then classified. SNVs agree among all the replicates are treated as 
concordant, and discordant if not. Concordant SNVs are more likely to be true SNVs 
rather than sequencing errors. The replicates could be technical, biological and cross-
platform. Taken biological replicates as an example, by plotting fraction of concordant 
and discordant SNVs on different thresholds of different filter metrics, such receiver–
operator characteristic curves can help evaluate the efficiencies of different filters and 
determine the threshold as well. 
  
1.3 NGS Based Low Frequency SNV Detection: Challenges and Existing Efforts 
The main challenges are how to reliably measure low frequency SNVs and how 
to distinguish from sequencing artifacts. Targeted deep sequencing can generate NGS 
data with per base coverage up to thousands or even higher, thus are more likely to 
capture low frequency SNVs. Amplicon based PCR target capture assay is the most 
common choice, and the target region usually ranges from tens (several kilobases) to 
hundreds of genes (up to several million bases). The development of benchtop 
sequencing systems such as Ion Torrent PGM, Ion Proton and Illumina MiSeq and 
NextSeq series, greatly promotes targeted sequencing and the development of target 
panels. However, tumors are genetically heterogeneous and often contain 
normal/stromal cells, which render some low-abundance somatic mutations close to or 
even below NGS detection limit. Targeted sequencing generates deep coverage on 
those loci but the amplification step keeps the original mutant to wildtype ratio in the 
tumor samples, with potential bias toward the wildtype allele. Methods that can 
selectively amplify the mutant allele have the potential to enrich these subtle signals. 
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COLD-PCR (co-amplification at lower denaturation temperature-PCR) [66-69] is a 
modified PCR protocol that identifies and enriches low-level mutant alleles in the 
presence of excess wildtype alleles, thus enabling the downstream analysis to identify 
real low-frequency variants. However, the feasibility to generalize COLD-PCR to a large 
number of sequences and sequences of various nucleotide compositions need to be 
carefully evaluated. Moreover, there is a recent report [70] of a sophisticated 
experimental protocol using target enrichment by sequential rounds of hybridization with 
biotinylated oligonucleotides, together with duplex sequencing described in section 1.2.3 
to increase the accuracy of calling rare variants. However, it is primarily applicable to 
small genomic intervals of the size of a single gene. Thus despite the promising results 
demonstrated from current protocol developments, more efforts in generalizing and 
standardizing these modified protocols are required for broader applications.  
In terms of bioinformatics methodologies, existing tools, such as VarScan2 [71], 
Strelka [72], and mutect [73], are mainly designed to target variants with lowest allele 
frequencies at 5% level for a whole exome or several hundreds of targeted genes 
sequenced with average depth around hundreds. Several studies focus on a small 
number of hotspot cancer genes with ultra-deep sequencing (greater than 10,000x in 
depth) [74, 75] for pushing down the detection limit. However, such methods usually take 
ad hoc filtering approach, and are designed to target variant identification within a small 
genomic region, usually less than 20,000 nt. In addition, existing methods typically use 
base quality to derive the base call error rate for each location assuming equal 
substitution error rates, and/or using an empirical mutational rate to derive the posterior 
probability or likelihood ratio of a location being a somatic mutation rather than a 
germline variant. Since the common parameters used didn’t consider differential error 
profile at different genomic loci across the targeted regions, such method is suboptimal 
in sensitively detecting variant with allele frequency close to intrinsic sequencing error 
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rate. Thus, additional ad hoc trimming, filtering and thresholding are often required to 
remove the variants with lower qualities. Such strategy significantly limits the 
generalizability of the analysis methods. Therefore, to our knowledge, no existing 
methods can reliably detect SNVs at close to 1% allele frequency using data from 
standard sequencing protocols targeting hundreds of genes. 
 
1.4 Appropriate Benchmarking for Low Frequency SNV Detection Methods 
Defining a gold standard benchmark for SNV detection is challenging since the 
benchmark needs to be completely characterized to include all real SNVs as well as to 
exclude false positive calls. Such a task is even more challenging for low-frequency 
somatic SNV detection since no tumor genome has been completely characterized and 
the depths of existing data usually are not deep enough to enable identifying low-
frequency SNVs. To address these problems, there are in general 4 types of approaches 
to simulate cancer genomes for benchmarking: (1) de novo simulation reads and 
mutations based on previously learnt sequencing error profiles on the basis a reference 
genome [76-80], (2) admixture of existing sequencing data from multiple samples at 
various percentages [23, 81], (3) bridging (1) and (2) where cancer genome reads are 
derived by modifying pre-existing alignments at desired frequencies and realigning the 
modified reads [82] and (4) mixing DNA samples with known genotypes at designed 
percentages and then sequence the DNA mixture [83]. These methods all have their 
own merits and demerits. Method (1) is cost-efficient since once the error profiles are 
learnt, it can generate new simulated sequencing data without actual sequencing cost. 
And it is flexible since simulated data can be generated for different platforms based on 
different error profiles. However the major problem with this method is that it cannot 
recapitulate biases and error profiles if they had not been well defined and 
characterized. This is a serious problem that limits its application value since different 
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combinations of sample preparation and sequencing technology may demonstrate 
differential biases and error profiles. Method (2) successfully avoids the problem in (1) 
by operating on existing sequencing data, thus the sequencing biases and error profiles 
are well preserved. However, there are concerns about method (2) arguing it is biased 
toward SNVs already detectable [82]. In addition, the allele-frequencies derived from in-
silico mixing step may not be an ideal representation of the actual biological cell 
subpopulations. The reason is the mechanisms causing such variations may be far more 
complicated than the in-silico mixing schemas. Method (3) tried to combine (1) and (2) to 
take advantages of both, however, this method ignores the context specific nature of 
sequencing error profiles [57, 60, 84]. Further, the rationale of retaining the same base 
qualities after changing bases at the same locus is open to doubt. Method (4) preserves 
the original sequencing biases and error profiles, especially the sequence context 
related errors. It can also provide information to evaluate the agreement between the 
observed allele frequencies and the actual abundance of corresponding cell populations, 
which is useful for determining the variability of allele frequencies estimated from 
sequencing data. In addition, compared with in-silico mixing, the DNA-mixing-followed-
by-sequencing approach allows characterization of potential bias toward wildtype allele, 
which may affect allele frequency estimation. For the purpose of benchmarking low-
frequency SNV callers, we choose method (4).  
 
1.5 Objectives 
The main objective of this thesis is to develop a computational framework to 
reliably identify low-frequency SNVs for applications in cancer or population genomics 
and genetics study. To serve the main objective of computational methodology 
development, three sub objectives were derived: design suitable benchmark for model 
training and testing, model sequencing errors to establish the lowest detection boundary 
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and decide the optimal classification boundary between true SNVs and technical 
artifacts to refine SNV calls.  
Chapter 2 describes in detail a novel experimental and computational modeling 
framework, which designed specific modules for each of the aforementioned sub 
objectives. The framework named RareVar aims to push the detection limit to allele 
frequencies as low as 0.5-1% under standard sequencing experiment protocols. This 
would significantly improve the sensitivity with which rare somatic mutations can be 
detected. The experimental part includes a strategy to construct benchmark tumor DNA 
samples containing thousands of SNVs with a wide range of allele frequencies yet 
enriched with low frequency variants (0.5%-3%). The benchmark tumor DNA samples 
are amplified and sequenced using the same protocol as the primary tumor samples, 
and are further used to construct a statistical model for deriving the background 
sequencing error rates that are specific to different genomic loci. This benchmark 
sample is further used for constructing a machine-learning-based model for variant 
recalibration. We evaluated the performance of RareVar together with several existing 
tools on an independent test benchmark. This analysis showed RareVar is more 
sensitive than other tools for variants at 3% or less allele frequencies.  
Chapter 3 described the ongoing project of applying our low-frequency SNV 
calling framework RareVar on studying mutational drift/enrichment of reprogrammed 
breast tumor cells.  
Chapter 4 explored the potential to improve the performances on identifying 
candidate SNVs with close to sequencing error rate frequencies by implementing more 
sophisticated statistical models for sequencing error characterization.  
Chapter 5 evaluated the generalizability and adaptiveness of the position specific 
sequencing error model. Instead of Ion Proton sequencing data used in previous 
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chapters, the model was tested on Illumina MiSeq platform, which utilized completely 
different biochemistries.  
  
14 
Chapter 2. RareVar: a Framework for Detecting Low Frequency Single Nucleotide 
Variants 
2.1 Overview of RareVar Framework 
The RareVar protocol includes five major components: benchmark sample 
design, target region amplification and sequencing, position specific sequencing error 
modeling (PSEM), variant identification, and machine-learning-based variant 
recalibration (Figure 1). A training benchmark sample was designed to contain a set of 
mutations at known allele frequencies in the desired capture regions. This benchmark 
sample was sequenced in parallel with the samples of interest using the exact same 
capturing and sequencing protocol and thus serves as a calibration set to evaluate the 
accuracy of the sequencing and analysis pipeline. The non-SNV loci in the benchmark 
sample provide data for PSEM on genomic features that distinguish low frequency SNVs 
from sequencing errors, while the known SNVs allow further adjustment of machine-
learning algorithms to recalibrate the variant calls based on features from the particular 
experimental procedures. 
In this chapter, the usage of RareVar framework is demonstrated under the 
scenario of detecting somatic SNVs from paired normal-tumor samples. Thus, both 
training and testing benchmarks contain 2 samples, one mimicking the normal sample 
and the other one mimicking the tumor sample. In the training benchmark, instead of 
using invariant loci data from tumor sample as the training data for position specific error 
modeling, the invariant loci data from normal sample sequencing data are used. The 
reason is we want to take advantage of the paired normal-tumor design, since the 
normal sample is less likely to contain potentially missed SNVs compared with the tumor 
sample that is generated by mixing DNAs from multiple individuals as described in 
section 2.2.1.  The SNV loci sequencing data in the tumor sample constitute the training 
data for machine-learning-based variant recalibration. 
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Figure 1 RareVar framework overview. During the training phase, genome contexts of 
invariant loci are used to train a position specific error model (PSEM). Then the 
genome contexts of all loci are fed to PSEM and the resultant predictions comprise the 
candidate SNV loci. Sequencing qualities of those candidates are used to further 
calibrate their fidelity. Actual data involved in model training are highlighted in dashed 
lines and boxes. During the testing phase, testing benchmark data go through the 
trained PSEM and recalibration model to generate high confidence SNVs. 
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2.2 Materials and Methods 
2.2.1 Benchmark Design 
A total of 22 DNA samples from the 1000 Genomes Project were selected. The 
genotype information is available for the selected individuals [85]. Two sets of 18 
samples were used, one for the training benchmark set and the other for the testing 
benchmark set (Table 1). For paired normal-tumor design, one sample was chosen as 
the normal sample, and then the 18 samples were pooled together at different 
percentages to mimic the tumor sample. Details are described below.  
The goal for the training benchmark tumor sample mixing design was to 
maximize the number of low frequency (0.5-3%) SNVs in the target regions. To achieve 
this goal, two steps were utilized. First, among one set of 18 DNA samples, we identified 
the one that has the largest number of overlapping SNVs with other samples in the 
target regions, which is NA11993 shown in Table 1. The SNVs from this sample were 
used to represent the germline mutations from normal/stromal cell population for somatic 
mutation identification. These SNVs are referred as “germline” SNVs and the sample is 
referred as “normal” sample in the later description. Second, for the tumor sample, the 
other 17 samples were mixed at varying concentrations (1% to 10%); samples with 
larger number of unique SNVs in the target regions were assigned lower concentrations 
(Table 1). The previously chosen normal sample represents normal cell population in the 
pooled tumor sample. Similarly, the testing benchmark tumor sample was designed by 
mixing another set of 18 DNA samples at concentrations different from the training 
samples. Four of the 18 samples in the testing benchmark were not in the training 
benchmark (Table 1 last 4 rows), and the three samples with higher number of unique 
SNVs were assigned 1% mixing percent while the remaining sample NA12878 was 
assigned the highest mixing percent. The SNVs from the new samples in the testing 
benchmark tumor sample comprised the subset to monitor potential model over-fitting 
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from both the position specific error model and the machine-learning step, where SNVs 
from the samples used in both training and testing comprised the subset to evaluate the 
performances on independent sequencing runs. The DNA mixing strategy for both 
training and test benchmark tumor samples are shown in Table 1. 
 
2.2.2 Sequencing 
The targeted regions for benchmark datasets included all exons of 409 known 
cancer-related genes, totaling about 1.7 million bases.  For library construction, targeted 
sequences were captured by ~ 16,000 amplicon primer pairs from Ion AmpliSeq 
Comprehensive Cancer Panel. The average length of amplicons is 155bp. The library 
was prepared using Ion AmpliSeq Library Kit 2.0. Sequencing was carried out on Ion 
Proton system, and the data was aligned to Human Genome reference hg19 by TMAP in 
Torrent Suite Software version 4.4.2. On target, uniquely mapped and mapping quality 
>= 40 reads were used in the following analyses.  
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Table 1 Design of tumor samples for training and testing benchmarks. Individual 
NA11993, shaded, was used as the normal sample in the training set; while shaded 
individual NA12878 was used as the normal sample in the testing set. ‘NA’ means not 
used.  
 Training Set Tumor Sample Testing Set Tumor Sample 
ID Number of Unique SNPs 
Mixing  
Percent 
Number of 
Unique SNPs 
Mixing  
Percent 
NA11993 37 0.47 NA NA 
NA18507 86 0.10 70 0.01 
NA12155 33 0.08 NA NA 
NA18563 37 0.06 NA NA 
NA12144 32 0.03 NA NA 
NA12750 42 0.03 43 0.10 
NA12751 42 0.03 38 0.06 
NA07000 39 0.03 43 0.06 
NA18987 44 0.03 44 0.03 
NA18965 48 0.02 43 0.08 
NA12872 51 0.02 45 0.03 
NA18622 44 0.02 44 0.03 
NA18853 72 0.02 60 0.01 
NA18526 48 0.02 58 0.01 
NA18870 109 0.01 102 0.02 
NA18502 107 0.01 90 0.02 
NA18871 99 0.01 85 0.02 
NA18501 95 0.01 75 0.02 
NA19239 NA NA 86 0.01 
NA12878 NA NA 41 0.46 
NA19238 NA NA 71 0.01 
NA19092 NA NA 65 0.01 
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2.2.3 Position Specific Error Rate Modeling 
In order to evaluate how genome contexts at specific genomic loci affect 
sequencing accuracy, a Poisson distribution generalized linear model (PD-GLM) was 
applied to model the relationship between specific genome contexts and error rates as 
shown in Equation (1),  
 
 log �𝐸𝐸�𝑛𝑛𝑙𝑙,𝑏𝑏,𝑠𝑠�� = log�𝑑𝑑𝑙𝑙,𝑠𝑠� + 𝛼𝛼 + 𝛽𝛽′���⃑ ∗ 𝑋𝑋𝑙𝑙,𝑏𝑏,𝑠𝑠���������⃑  (1) 
 
where 𝑛𝑛𝑙𝑙,𝑏𝑏,𝑠𝑠  is the number of reads in location 𝑙𝑙  within the target regions that 
support non-reference base 𝑏𝑏  on strand 𝑠𝑠  (forward or reverse), 𝑑𝑑𝑙𝑙,𝑠𝑠  is the depth of 
sequencing at location 𝑙𝑙 on strand 𝑠𝑠, and 𝑋𝑋𝑙𝑙,𝑏𝑏,𝑠𝑠���������⃑  is a vector of co-variants that describes 
different aspects of genomic context surrounding the candidate loci. In addition, 𝛼𝛼 and 𝛽𝛽 
are the intercept and coefficients of the regression for the co-variates, which indicate the 
contribution of each factor to the sequencing error rate. The training data for PD-GLM 
contain the loci that have a depth within 25% to 75% quantile and alternative allele 
frequency no more than 1.5%, totaling ~ 5 million records. 
PD-GLM integrated 9 genome context features (Table 2) previously reported to be 
related to sequencing errors [57, 61], including alternative base substitution types, the 
nucleotides immediate upstream and downstream of the variant loci, the percentage of 
GC nucleotides in the nearby region by extending 50 bases upstream and 50 bases 
downstream of the target nucleotide. In addition, features related to homopolymer of the 
loci were also considered, including the length of the closest homopolymer, the distance 
from the SNV to the closest homopolymer (defined as the number of bases from the 
target nucleotide to the closest base in the homopolymer, specifically, the homopolymer 
could be upstream/downstream or could contain the locus of interest) and the fraction of 
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bases within homopolymers in the nearby region by extending 15 bases upstream and 
15 bases downstream of the target nucleotide. The homopolymer features are designed 
to capture the intuition that other than nucleotide contexts (substitution, upstream, 
downstream bases and GC content), sequencing data for a locus tend to be erroneous if 
it is near the boundary of one or more long homopolymer(s). 
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Table 2 Definition of features in the PSEM step and summary of regression.  
Features Definition Degrees of Freedom1 Covariates
2 Estimated Coefficients 
Standard 
Error3 
P 
Value4 
NA 
Intercept only model, containing the 
baseline for each feature. Specifically: 
substitution is A > C, upstream and 
downstream bases are both A; GC, 
hmer_dist, hmer_len, hden, hrun_op and 
alt_up_down_eq are all 0. 
1 Intercept -11.030 0.0079 < 2e-16 
substitution 
Change from reference base to 
alternative base; there are 12 possible 
values. A > G means reference base A 
to alternative base G. 
11 
A > G 1.621 0.0049 < 2e-16 
A > T 0.123 0.0063 < 2e-16 
C > A 0.046 0.0065 1.8e-12 
C > G -0.184 0.0070 < 2e-16 
C > T 1.399 0.0051 < 2e-16 
G > A 1.326 0.0051 < 2e-16 
G > C -0.071 0.0068 < 2e-16 
G > T -0.022 0.0066 9.1e-04 
T > A 0.190 0.0062 < 2e-16 
T > C 1.633 0.0049 < 2e-16 
T > G 0.134 0.0061 < 2e-16 
upstream 
base 
Immediate upstream base (4 possible 
values: A,C,G,T). 3 
C 0.115 0.0026 < 2e-16 
G 0.247 0.0025 < 2e-16 
T -0.127 0.0027 < 2e-16 
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Features Definition Degrees of Freedom1 Covariates
2 Estimated Coefficients 
Standard 
Error3 
P 
Value4 
downstream 
base 
Immediate downstream base (4 possible 
values: A,C,G,T). 3 
C 0.475 0.0027 < 2e-16 
G 0.308 0.0027 < 2e-16 
T 0.118 0.0028 < 2e-16 
GC content 
Percent of GC bases within a 101 base 
window that extends 50 nucleotides both 
upstream and downstream.  
1 GC 0.005 0.0001 < 2e-16 
distance to 
the closest 
homopolymer
5 base 
Number of nucleotides to the closest 
base of the homopolymer within a 
window that extends 15 bases both 
upstream and downstream (possible 
values 0 to 13, 15 for no homopolymer 
within the window). 
1 hmer_dist -0.009 0.0003 < 2e-16 
length of the 
closest 
homopolymer 
Length of the closest homopolymer 
within a window that extends 15 bases 
both upstream and downstream 
(possible values 0, 3, 4 to 31). 
1 hmer_len 0.081 0.0009 < 2e-16 
homopolymer 
bases 
percentage 
Fraction of bases within a 31 bases 
window that are in homopolymers 
(possible values 0, 3/31, 4/31 to 1). The 
window extends 15 bases both 
upstream and downstream. 
1 hmer_percent 0.193 0.0095 < 2e-16 
overlap with 
homopolymer 
Whether the locus of interest is within a 
homopolymer, 1 means yes, 0 means 
no. 
1 hmer_op 0.375 0.0026 < 2e-16 
upstream or 
downstream 
base shift 
Whether the alternative base is the 
same as the immediate upstream or 
downstream base, 1 means yes, 0 
means no. 
1 alt_up_down 0.690 0.0019 < 2e-16 
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1: Degrees of Freedom: The number of covariates for each feature in the PD-GLM model. For categorical features, this is the number 
of possible levels minus 1 while for numerical features degrees of freedom equal 1. 
2: Covariates: symbols for all features used in PD-GLM. These are the variable names used in the generalized linear model. 
3: Standard Error: the standard error of the estimated PD-GLM coefficients. 
4: P Value: significance of each covariate. 
5: homopolymer: a consecutive sequence of at least 3 identical bases. 
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2.2.4 Variant Identification 
We applied a Bayesian-based approach for identifying variants with low allele 
frequencies, based on the number of reads supporting alternative allele at each specific 
genomic locus, and its estimated position-specific error rate. For each candidate variant 
locus, a Bayes factor was calculated by comparing the likelihood ratio of two competing 
models - ME and MV. ME represents the model that the number of alternative reads 
follows ‘sequencing error distribution’ - PD-GLM estimated position-specific sequencing 
error. Whereas MV represents the model that the number of alternative reads follows the 
‘targeted lowest identifiable frequency distribution’ - a SNV at the frequency of the 
targeted lowest identifiable allele frequency more than PD_GLM predicted error. In this 
study, our targeted lowest frequency is f = 0.5%. In Equation (2) 𝑛𝑛𝑙𝑙,𝑏𝑏,𝑠𝑠 and 𝑑𝑑𝑙𝑙,𝑠𝑠 remain the 
same as in Equation (1). In addition, 𝜆𝜆𝐸𝐸,𝑙𝑙,𝑏𝑏,𝑠𝑠 and 𝜆𝜆𝑉𝑉,𝑙𝑙,𝑏𝑏,𝑠𝑠 represent the expected number of 
alternative reads assuming the candidate locus is not an SNV (𝑛𝑛𝑙𝑙,𝑏𝑏,𝑠𝑠 ~ 𝑃𝑃𝑃𝑃𝑃𝑃(𝜆𝜆𝐸𝐸,𝑙𝑙,𝑏𝑏,𝑠𝑠)), and 
is an SNV with the lowest intended identifiable allele frequency (𝑛𝑛𝑙𝑙,𝑏𝑏,𝑠𝑠 ~ 𝑃𝑃𝑃𝑃𝑃𝑃(𝜆𝜆𝑉𝑉,𝑙𝑙,𝑏𝑏,𝑠𝑠)),), 
respectively. An observed substitution type in a location is considered a SNV candidate 
if Bayes factors 𝐵𝐵𝐵𝐵𝑙𝑙,𝑏𝑏,𝑠𝑠 for both strands are greater than 100. This threshold implies that 
on each strand it is 100 times more likely that a specific position is a variant than that it is 
a sequencing error. We evaluated the precision, recall and F1 scores at different Bayes 
factor thresholds, including any number that is a power of 2 within 2 to 512, together with 
10, 50, 100, 200, 300, 400 and 500. Figure 2 upper panel showed recall dropped with 
increasing thresholds while the precision increased. The lower panel showed harmonic 
mean of precision and recall – F1 score increased with bigger thresholds. However, the 
increase in F1 score began to significantly slow down around 64 to 128, as highlighted 
by the tangential line at 100. Thus the performance gain by setting more stringent 
threshold became smaller. Since the variant identification step aims at identifying SNV 
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candidates, we chose 100 as the threshold to efficiently gain increase in precision and 
left the candidate refinement to the next step. 
 
𝐵𝐵𝐵𝐵𝑙𝑙,𝑏𝑏,𝑠𝑠 =  𝑃𝑃𝑃𝑃�𝑛𝑛𝑙𝑙,𝑏𝑏,𝑠𝑠�𝑀𝑀𝑉𝑉�𝑃𝑃𝑃𝑃�𝑛𝑛𝑙𝑙,𝑏𝑏,𝑠𝑠�𝑀𝑀𝐸𝐸� =  ∑ 𝜆𝜆𝑉𝑉,𝑙𝑙,𝑏𝑏,𝑠𝑠
𝑘𝑘 𝑒𝑒−𝜆𝜆𝑉𝑉,𝑙𝑙,𝑏𝑏,𝑠𝑠𝑛𝑛𝑙𝑙,𝑏𝑏,𝑠𝑠𝑘𝑘=0
𝑘𝑘!1 − ∑ 𝜆𝜆𝐸𝐸,𝑙𝑙,𝑏𝑏,𝑠𝑠𝑘𝑘 𝑒𝑒−𝜆𝜆𝐸𝐸,𝑙𝑙,𝑏𝑏,𝑠𝑠𝑛𝑛𝑙𝑙,𝑏𝑏,𝑠𝑠𝑘𝑘=0 𝑘𝑘! , 
 𝜆𝜆𝑉𝑉,𝑙𝑙,𝑏𝑏,𝑠𝑠 =  𝜆𝜆𝐸𝐸,𝑙𝑙,𝑏𝑏,𝑠𝑠 + 𝑑𝑑𝑙𝑙,𝑠𝑠 ∗ 𝑓𝑓 (2) 
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Figure 2 Performance metrics at various thresholds of Bayes factor.Upper panel 
shows the precision (bottom line) and recall (top line) at various thresholds. Lower 
panel shows the F1 score at various thresholds. The green line in the lower panel is 
the tangent line of the curve at threshold 100. 
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2.2.5 Machine-Learning Based SNV Calibration 
SNV candidates at the lower frequencies from the variant identification step still 
contain a large number of false positives. It has been observed previously that 
sequencing-related measurements, such as sequencing and alignment quality, have a 
strong influence on the accuracy of variant identity [65]. Instead of setting up a series of 
hard filtering criteria for different measurements, a strategy utilized by many earlier 
methods, we adopted a machine learning-based approach to derive an optimal 
classification boundary between false positives and true ones by simultaneously 
modeling multiple measurements. This strategy takes the advantage of the benchmark 
dataset we constructed, since true and false positives of the identified candidate variants 
in these samples are known. Since the PSEM model focused on the genomic features 
surrounding the variant loci, in this second step, we further explored the measurements 
related to the experimental and analytical steps. Many of these features have been 
reported useful in ruling out false positives in previous studies [65, 71, 72, 86] (Table 3). 
The features included in the machine-learning model can be grouped into the following 
generic types: sequencing, alignment, amplicon structure and genome context related 
features from PSEM. Information gain (IG) [87] was used to rank the classification power 
of all features and is defined in Equation (3), where 𝐶𝐶 is the two classes: true SNVs or 
noise; 𝐻𝐻(𝐶𝐶) is the information entropy for all classes, 𝐻𝐻(𝐶𝐶|𝑓𝑓𝑒𝑒𝑓𝑓𝑓𝑓𝑓𝑓𝑃𝑃𝑒𝑒) is the conditional 
information entropy for all classes given a feature; 𝑥𝑥  is a categorical feature with 𝑘𝑘 
levels, where numerical features are discretized with Fayyad & Irani's MDL method [88]. 
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Table 3 RareVar: features considered in variants recalibration step. Features are ranked based on column 'Information Gain'. 
Genome context features are from the PSEM step.  
Feature Explanation Category Information Gain Source 
Allele_Freq Allele frequency Sequencing. 0.363 RareVar 
MisMatch_Percent 
For reads containing alternative base, the 
percent of reads also containing other 
mismatches within a 11 base window. 
Alignment. 0.300 RareVar 
MAPQ_Alt_RefDiff 
Difference of average mapping quality 
between reads containing alternative and 
reference. 
Alignment. 0.220 RareVar 
MAPQ_Avg_Alt Average mapping quality for reads containing alternative base. Alignment. 0.197 RareVar 
BaseQ_Avg_Alt Average base quality for alternative bases. Sequencing. 0.190 RareVar 
MAPQ_RankSum Rank sum test of mapping quality. Alignment. 0.177 GATK 
BaseQ_RankSum Rank sum test of base quality. Sequencing. 0.130 GATK 
BaseQ_Alt_RefDiff Difference of average base qualities between alternative and reference bases Sequencing. 0.117 RareVar 
Fisher_SB Fisher exact test of strand bias. Sequencing. 0.106 GATK 
AbsDiff_StrandAF_Percent Absolute value of the difference in allele frequencies between two strands Sequencing. 0.102 RareVar 
Substitution Change from reference base to alternative base. Genome context. 0.073 RareVar 
Strand_OR Odds ratio of reads supporting alternative and reference alleles in two strands. Sequencing. 0.068 RareVar 
Hmer_dist Distance to the closest homopolymer base. Genome context. 0.064 GATK 
Alt_up_down Upstream or downstream base shift Genome context. 0.053 RareVar 
BaseQ_Avg_Ref Average reference base quality. Sequencing. 0.049 RareVar 
Hmer_op Overlap with homopolymer. Genome context. 0.047 RareVar 
Feature Explanation Category Information Source 
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Gain 
Hmer_len Length of the closest homopolymer. Genome context. 0.046 RareVar 
Fwd_WDis Forward strand weighted distance to amplicon ends. Amplicon. 0.035 RareVar 
Fwd_Read_Percent Percent of forward strand reads supporting alternative allele. Sequencing. 0.034 RareVar 
Rev_WDis Reverse strand weighted distance to amplicon ends. Amplicon. 0.032 RareVar 
ReadPos_RankSum Rank sum test of alternative allele position in reads. Sequencing. 0.032 GATK 
Up_base Immediate upstream base. Genome context. 0.030 RareVar 
Down_base Immediate downstream base. Genome context. 0.029 RareVar 
HDen 
Homopolymer density, the percent of 
homopolymer bases within a 31 bp 
window. 
Genome context. 0.025 RareVar 
MAPQ_Avg_Ref Average mapping quality for reads containing reference allele.  Alignment. 0.016 RareVar 
Quality_Depth SNP confidence normalized by unfiltered depth of snp samples. Sequencing. 0.015 GATK 
Avg_NMM_perRead 
Average number of other mismatches in 
reads containing alternative allele within 
a 11 bases window. 
Alignment. 0.014 RareVar 
RMS_MAPQ Root Mean Square of the mapping quality of reads. Alignment. 0.01 GATK 
GC Content 
Percent of GC bases within a 101 base 
window that extends 50 nucleotides both 
upstream and downstream.  
Genome context. 0.000 GATK 
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𝐼𝐼𝐼𝐼 = 𝐻𝐻(𝐶𝐶) −𝐻𝐻(𝐶𝐶|𝑓𝑓𝑒𝑒𝑓𝑓𝑓𝑓𝑓𝑓𝑃𝑃𝑒𝑒) 
      = −�𝑃𝑃�𝑐𝑐𝑗𝑗�𝑙𝑙𝑃𝑃𝑙𝑙𝑃𝑃�𝑐𝑐𝑗𝑗�2
𝑗𝑗=1
+ �𝑃𝑃(𝑥𝑥𝑖𝑖)�𝑃𝑃�𝑐𝑐𝑗𝑗|𝑥𝑥𝑖𝑖�𝑙𝑙𝑃𝑃𝑙𝑙𝑃𝑃�𝑐𝑐𝑗𝑗|𝑥𝑥𝑖𝑖�2
𝑗𝑗=1
𝑘𝑘
𝑖𝑖=1
 (3) 
 
Machine-learning algorithm ‘random forest’ [89] from the software Weka [90] was 
employed to incorporate all features to train the classifier that best distinguishes false 
positive SNVs from true positive ones. The Random forest algorithm is employed with 
100 trees, maximum 𝑙𝑙𝑃𝑃𝑙𝑙2(𝑛𝑛𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓) + 1 features (𝑛𝑛𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 is the total number of features) 
to consider in each tree and no limitation on depth of the trees. The output of the 
classifier is a probability that a candidate SNV being a true SNV. The threshold is 0.5, 
thus if classification probability is greater than 0.5 then the candidate SNV is considered 
to be a true SNV. 
 
2.2.6 Performance Evaluation 
The AmpliSeq Comprehensive Cancer Panel targets exonic regions of known 
cancer related genes. Exonic loci with at least 5 reads supporting an alternative allele 
are included in the evaluation (Table 4). Precision and recall are defined in Equations (4) 
and (5). The allele frequency ranges were determined by the observed values for 
precision and expected values from test benchmark for recall. 
 
 
𝑝𝑝𝑃𝑃𝑒𝑒𝑐𝑐𝑃𝑃𝑠𝑠𝑃𝑃𝑃𝑃𝑛𝑛 =  𝑃𝑃𝑒𝑒𝑐𝑐𝑃𝑃𝑟𝑟𝑒𝑒𝑃𝑃𝑒𝑒𝑑𝑑 𝑓𝑓𝑒𝑒𝑠𝑠𝑓𝑓 𝑏𝑏𝑒𝑒𝑛𝑛𝑐𝑐ℎ𝑚𝑚𝑓𝑓𝑃𝑃𝑘𝑘 𝑆𝑆𝑆𝑆𝑆𝑆𝑠𝑠
𝑝𝑝𝑃𝑃𝑒𝑒𝑑𝑑𝑃𝑃𝑐𝑐𝑓𝑓𝑒𝑒𝑑𝑑 𝑛𝑛𝑓𝑓𝑚𝑚𝑏𝑏𝑒𝑒𝑃𝑃 𝑃𝑃𝑓𝑓 𝑆𝑆𝑆𝑆𝑆𝑆𝑠𝑠  (4) 
 
𝑃𝑃𝑒𝑒𝑐𝑐𝑓𝑓𝑙𝑙𝑙𝑙 =  𝑃𝑃𝑒𝑒𝑐𝑐𝑃𝑃𝑟𝑟𝑒𝑒𝑃𝑃𝑒𝑒𝑑𝑑 𝑓𝑓𝑒𝑒𝑠𝑠𝑓𝑓 𝑏𝑏𝑒𝑒𝑛𝑛𝑐𝑐ℎ𝑚𝑚𝑓𝑓𝑃𝑃𝑘𝑘 𝑆𝑆𝑆𝑆𝑆𝑆𝑠𝑠
𝑒𝑒𝑥𝑥𝑝𝑝𝑒𝑒𝑐𝑐𝑓𝑓𝑒𝑒𝑑𝑑 𝑛𝑛𝑓𝑓𝑚𝑚𝑏𝑏𝑒𝑒𝑃𝑃 𝑃𝑃𝑓𝑓 𝑓𝑓𝑒𝑒𝑠𝑠𝑓𝑓 𝑏𝑏𝑒𝑒𝑛𝑛𝑐𝑐ℎ𝑚𝑚𝑓𝑓𝑃𝑃𝑘𝑘 𝑆𝑆𝑆𝑆𝑆𝑆𝑠𝑠 (5) 
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2.2.7 Parameter Customization for Existing Tools 
Existing tools to be compared with include TVC from Torrent Suite software, 
designed for Ion Proton sequencing data, Strelka and VarScan2. 
TVC version 4.4-8 from Torrent Suite version 4.4.2: customized parameter 
setting was used since the default setting from TVC (Table 5) excludes SNV candidates 
with less than 3.5% (parameter gen-min-alt-allele-freq [91]) allele frequency. The 
minimal mapping quality for a read to be considered parameter ‘MAPQ’ was set to be 
the same as RareVar. There is no option for turning off ‘downsample’, thus the maximum 
depth (34,223) in test benchmark data was used. 
Strelka [72] version v1.0.14: parameter file for bwa aligner was used. Depth filter 
on high-depth loci (isSkipDepthFilters [92]) was turned off. Also, since low recall was 
observed for <= 3% SNVs, combinations of ‘ssnvPrior’ and ‘ssnvNoise’ were tested. 
‘ssnvPrior’ specifies the prior probability of a locus containing somatic SNVs while 
‘ssnvNoise’ specifies the prior probability of a locus containing sequencing noise. The 
conclusion from this combinatory exploration suggested elevated ‘ssnvNoise’ decreases 
precision and recall while elevated ‘ssnvPrior’ increases recall with a slight drop in 
precision. The 1000x bigger ‘ssnvPrior’ results in ~ 3% increase in recall and ~ 1% drop 
in precision and since the extent of change is small, no further increase was attempted.  
VarScan [71] version v2.3.7: the parameter for minimal SNV allele frequency 
(‘min-var-freq’ [93]) was set to 0.5% and minimal number of reads supporting alternative 
allele (‘min-reads2’) was set to 5 to be consistent with RareVar. Since the percentage of 
DNA from test benchmark ‘normal’ sample individual was 0.46, thus the parameter 
specifying the percent of tumor cell population (‘tumor-purity’) was set to 0.54. The 
complete list of parameters is in Table 5. 
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Table 4 RareVar benchmark results: number of somatic SNVs by frequencies.  
 Training Benchmark Testing Benchmark 
AF SNVs Training UR1 Rate SNVs Testing UR Rate 
0.5% 394 304 22.84% 388 270 30.41% 
1% 319 271 15.05% 389 309 20.57% 
1.5 to 3% 414 360 13.04% 569 493 13.36% 
3.5 to 5% 185 162 12.43% 189 164 13.23% 
5.5 to 10% 227 213 6.17% 161 151 6.21% 
10.5 to 53% 170 151 11.18% 186 170 8.60% 
All 1709 1461 14.51% 1882 1557 17.27% 
1: UR stands for under-represented. A benchmark SNV is considered under-represented 
if fewer than 5 reads supporting the alternative allele.
 33 
Table 5 Adjusted parameters for tools compared with RareVar.  
Parameter Definition1 Default Value Customized Value Tool Name 
snp-min-allele-freq 
Minimum observed allele frequency 
required for a non-reference variant 
call. 
0.02 0.005 TVC 
gen-min-alt-allele-freq Filter out variant candidates that do not have at least this frequency. 0.035 0.0025 TVC 
MAPQ Minimum mapping quality. 4 40 TVC 
downsample Reduce coverage in high-depth locations to this value. 2,000 34,223 TVC 
isSkipDepthFilters Binary tag to filter loci with high depth. 1 means no filtering. 0 1 Strelka 
ssnvPrior Prior probability of a locus contains somatic SNV. 1.00E-06 1.00E-03 Strelka 
ssnvNoise Prior probability of a locus contains sequencing noise. 5.00E-07 5.00E-07 Strelka 
min-var-freq Minimal SNV allele frequency. 0.2 0.005 VarScan 
tumor-purity Percent of tumor cell population. 1 0.54 VarScan 
min-reads2 Minimal number of reads supporting the alternative allele. 2 5 VarScan 
1: Definitions were adapted from documents for each tool. 
34 
2.3 Results 
2.3.1 Benchmark Data Evaluation 
After filtering reads with mapping quality less than 40, about 79 and 68 million 
reads were used for training benchmark normal and mixed tumor samples, respectively, 
and about 59 and 64 million reads were used for testing benchmark normal and tumor 
samples, respectively. The design of benchmark sets generates 1,709 and 1,882 
somatic SNVs in the training and testing benchmarks, respectively. The design also 
ensures evaluation of SNVs with a broad range of allele frequencies, with special 
attention to the low frequency (0.5-3%) SNVs.  As shown in Table 4, the percent of 
somatic SNVs with allele frequency no more than 3% is 65.9% in training benchmark 
and 71.5% in testing benchmark. Somatic SNVs with fewer than 5 reads supporting 
alternative allele were considered under-represented, and were excluded from training 
and testing dataset. 
We checked the allele frequency agreement between sequenced benchmark 
tumor samples and the design. Potential SNV allele frequency bias introduced by 
pipetting variation in the pooling step was evaluated by the correlation of the detected 
median allele frequencies of SNVs unique to each individual with their designed 
frequencies (Table 1). The log scale linear regression analysis showed the individuals 
with smaller assigned percentages tend to have a slightly lower than the design 
percentages, with R2 > 0.98 for both training and testing benchmarks (Figure 3). Thus 
the observed allele frequencies highly correlated with the design, we used the 
benchmark datasets for further modeling building and performance evaluation. 
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Figure 3 Evaluation of pipetting variance in construction of the training and testing 
benchmarks. Numbers next to the dots represent the mixing frequencies of DNA 
samples; the line at 45 degrees represents perfect pipetting (observed frequency 
exactly equals the expected). The R2 for both training and testing benchmarks are from 
the linear regression results of using observed frequency in log10 scale as response 
variable – denoted by y and mixing frequency in log10 scale as explanatory variable – 
denoted by x. The coefficients for the explanatory variable are 1.025 (y = 1.025x) and 
1.030 (y = 1.030x) for training and testing benchmarks, respectively.   
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2.3.2 Position Specific Error Model and Variant Identification 
For each nucleotide different from the reference in each locus, a Poisson 
distribution generalized linear model (PD-GLM) was used to model the strand-specific 
sequencing error rate based on the associated genomic features (Table 2). Regression 
results showed all 9 features tested were statistically significant (p values < 0.001) in 
contributing to sequencing errors. Overall, the fitted model showed significant 
improvement compared to an intercept-only model (with no features considered), with 
Cragg & Uhler’s [94]  R2 = 0.246, indicating an excellent fit for R2 between 0.2 ~ 0.4 [95, 
96]. The signs and relative magnitudes of coefficients agreed with prior knowledge and 
the intuition derived from visualization. Take the feature substitution as an example, 
clear transitional bias, or purine/pyrimidine conservation was supported by the PD-GLM 
since four substitution types (A > G, C > T, G > A, T > C) have the largest positive 
coefficients (Table 2). As for the neighbor nucleotide composition complexity effect, 
slightly increasing error rates were observed for higher GC content values (Figure 4 top 
left) and this observation is also reflected in the small positive coefficient value (𝛽𝛽𝐺𝐺𝐺𝐺= 
0.005).  Also, if the alternative base is the same as the immediate upstream or 
downstream (for example a trinucleotide pattern CTG, the center base T changes to 
either upstream letter C or downstream letter G), these alternative bases observed are 
more likely to be context-induced errors (𝛽𝛽𝑓𝑓𝑙𝑙𝑓𝑓_𝑓𝑓𝑢𝑢_𝑑𝑑𝑑𝑑𝑑𝑑𝑛𝑛 = 0.690). For homopolymer related 
features, a locus is more erroneous if it is within 2 nucleotides of more long 
homopolymer(s) (𝛽𝛽ℎ𝑚𝑚𝑓𝑓𝑓𝑓_𝑑𝑑𝑖𝑖𝑠𝑠𝑓𝑓  = -0.009, 𝛽𝛽ℎ𝑚𝑚𝑓𝑓𝑓𝑓_𝑙𝑙𝑓𝑓𝑛𝑛  = 0.081, 𝛽𝛽ℎ𝑚𝑚𝑓𝑓𝑓𝑓_𝑢𝑢𝑓𝑓𝑓𝑓𝑝𝑝𝑓𝑓𝑛𝑛𝑓𝑓  = 0.193), and 
within a homopolymer (hmer_op = 0.375) (Figure 4 top right and bottom subplots). The 
magnitudes of the above-mentioned covariates indicate (1) if a candidate SNV locus is 1 
nucleotide further from a neighbor homopolymer then the error rate in natural log scale 
drops by 0.009, (2) if the neighbor homopolymer length increases by 1 nucleotide then 
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the error rate in natural log scale increases by 0.081, (3) if the percent of homopolymer 
bases increases by 0.1 (range 0 to 1) then the error rate in natural log scale increases 
by 0.193*0.1 = 0.0193 and (4) if the locus is within a homopolymer then the error rate in 
natural log scale increases by 0.375. 
After fitting the PSEM using PD-GLM, a Bayes factor was calculated for each 
base in each locus to determine its likelihood ratio of being a somatic SNV (from model 
MV) rather than a sequencing error (from model ME). To evaluate the efficacy of the 
PSEM in identifying SNV candidates, we mainly compared the performance of PSEM 
with Fisher’s Exact Test based VarScan2 [71]. VarScan2 was picked for comparison 
here because different from other tools (Strelka and TVC) that utilized sequencing 
quality features to boost precision at the cost of reduced recall, VarScan2 only considers 
the depth and number of reads supporting the alternative allele at the same genomic 
position of the two samples being compared. Thus the underlying features utilized by 
VarScan2 are genomic sequence contexts determined at each locus, which are the 
features that PSEM utilized explicitly. Therefore, both VarScan2 and PSEM should be 
able to recover the most number of true SNVs, which will be reflected in higher recall, 
especially in lower frequency ranges. In Table 6A comparing recall of different tools, we 
did observe PSEM and VarScan2 standing out as top 2 tools in overall recall and also 
showing large advantages over Strelka and TVC in 0.5% to 3% allele frequency ranges. 
Further, compared with VarScan2, PSEM showed higher overall recall (95.8% versus 
83.0%), with the advantages more evident at 0.5% (22.6% increase) and 1% (15.2% 
increase) ranges. However, comparing precision in Table 6B PSEM and VarScan2 
showed lowest precision, especially at in 0.5% to 3% allele frequency ranges. Thus, 
despite the high efficiency of PSEM in recovering candidate SNVs, sequencing related 
features needed to be incorporated into the SNV caller for candidate recalibration. 
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Figure 4 Relationship between genomic context features and error rate. The error rate is 
the mean of error rates from all data with a certain feature value, for example 
homopolymer length 7. For feature values with less than 1000 points, the points are 
combined to derive the mean error rate. The line is the smoothed trend line. The details 
of the features are described in Table 2. 
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Table 6 RareVar: Comparison of recall and precision for different allele frequencies.  
A: Recall comparison        VarScan22 PSEM3 
Expected 
Frequency
1 
Expected 
Number 
of SNVs 
Recovered 
Number of 
SNVs 
Recall 
Expected 
Number 
of SNVs 
Recovered 
Number of 
SNVs 
Recall 
0.5% 270 169 62.6% 270 230 85.2% 
1% 309 249 80.6% 309 296 95.8% 
1.5 to 3% 493 438 88.8% 493 483 98.0% 
3.5 to 5% 164 148 90.2% 164 162 98.8% 
5.5 to 10% 151 137 90.7% 151 150 99.3% 
10.5 to 54% 170 152 89.4% 170 170 100.0% 
All 1557 1293 83.0% 1557 1491 95.8% 
  Strelka2 RareVar4 
Expected 
Frequency
1 
Expected 
Number 
of SNVs 
Recovered 
Number of 
SNVs 
Recall 
Expected 
Number 
of SNVs 
Recovered 
Number of 
SNVs 
Recall 
0.5% 270 0 0.0% 270 96 35.6% 
1% 309 0 0.0% 309 251 81.2% 
1.5 to 3% 493 121 24.5% 493 458 92.9% 
3.5 to 5% 164 138 84.1% 164 156 95.1% 
5.5 to 10% 151 141 93.4% 151 149 98.7% 
10.5 to 54% 170 160 94.1% 170 165 97.1% 
All 1557 560 36.0% 1557 1275 81.9% 
  TVC2 
Expected 
Frequency
1 
Expected 
Number 
of SNVs 
Recovered 
Number of 
SNVs 
Recall 
0.5% 270 7 2.6% 
1% 309 88 28.5% 
1.5 to 3% 493 429 87.0% 
3.5 to 5% 164 158 96.3% 
5.5 to 10% 151 146 96.7% 
10.5 to 54% 170 166 97.6% 
All 1557 994 63.8% 
1: SNV frequencies are based upon the mixing scheme in Table 1. 
2: The customized parameters applied are listed in Table 5. 
3: PSEM represents the intermediate results of RareVar framework candidate SNV 
calling step using Bayes factor. 
4: RareVar contains both PSEM and machine-learning base recalibration steps.  
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B: Precision comparison       VarScan22 PSEM3 
Expected 
Frequency
1 
Predicte
d 
Number 
of SNVs 
Recovered 
Number of 
SNVs 
Precision 
Predicte
d 
Number 
of SNVs 
Recovered 
Number of 
SNVs 
Precis
ion 
0.25 to 
0.75% 1105 223 20.2% 1369 286 20.9% 
0.75 to 
1.25% 389 256 65.8% 479 298 62.2% 
1.25 to 3% 449 368 82.0% 571 422 73.9% 
3 to 5% 175 158 90.3% 217 168 77.4% 
5 to 10% 158 144 91.1% 207 159 76.8% 
10 to 54% 149 144 96.6% 190 158 83.2% 
All 2425 1293 53.3% 3033 1491 49.2% 
  Strelka2 RareVar4 
Expected 
Frequency
1 
Predicte
d 
Number 
of SNVs 
Recovered 
Number of 
SNVs 
Precision 
Predicte
d 
Number 
of SNVs 
Recovered 
Number of 
SNVs 
Precis
ion 
0.25 to 
0.75% 0 0 NA 140 127 90.7% 
0.75 to 
1.25% 0 0 NA 271 264 97.4% 
1.25 to 3% 89 84 94.4% 417 403 96.6% 
3 to 5% 190 167 87.9% 172 165 95.9% 
5 to 10% 182 157 86.3% 169 159 94.1% 
10 to 54% 162 152 93.8% 166 157 94.6% 
All 623 560 89.9% 1335 1275 95.5% 
  TVC2 
Expected 
Frequency
1 
Predicte
d 
Number 
of SNVs 
Recovered 
Number of 
SNVs 
Precision 
0.25 to 
0.75% 1 0 0.0% 
0.75 to 
1.25% 104 97 93.3% 
1.25 to 3% 454 420 92.5% 
3 to 5% 194 183 94.3% 
5 to 10% 189 176 93.1% 
10 to 54% 170 163 95.9% 
All 1112 1039 93.4% 
1: SNV frequencies are based upon the percent of reads supporting alternative allele 
from sequencing. 
2: The customized parameters applied are listed in Table 5. 
3: PSEM represents the intermediate results of RareVar framework candidate SNV 
calling step using Bayes factor. 
4: RareVar contains both PSEM and machine-learning base recalibration steps. 
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2.3.3 Machine Learning Based SNVs Calibration 
In order to further reduce the number of false positive SNVs identified using the 
PSEM, we utilized a machine-learning model – Random Forest [89] to better distinguish 
true positive and false positive SNVs. We used information gain to rank the classification 
power of 29 measurements related to sequencing technology and downstream analysis 
methods together with all features from PSEM. Sequencing-related features and 
alignment quality features ranked the highest, while GC content was removed due to 0 
information gain (Table 3).  
The machine-learning-based variant recalibration effectively reduced false 
positive SNVs identified by the PSEM alone. In the testing benchmark dataset, the 
overall precision increased from 49.2% (after the PSEM model) to 95.5% (after machine-
learning refinement, represented as RareVar in Table 6), with the overall recall rate 
dropped from 95.8% to 81.9%.  
 
2.3.3.1 Performance by allele frequencies 
A closer examination of the RareVar performance by allele frequencies showed 
the precision increased for all allele frequencies by at least 10% after machine-learning-
based variant recalibration (represented as RareVar in Table 6) compared with PSEM 
alone, with greater than 90% precision achieved for SNVs in all allele frequency ranges 
(Table 6B). As expected, lower frequencies showed higher increase, in which 0.70 and 
0.35 increases in precision were achieved for 0.5% and 1%, resulting in 90.7% and 
97.4% precision respectively. The decrease in recall was mainly attributed to 0.5% and 
1%, yet > 80% recall was maintained for allele frequencies ≥ 1%. The ROC curve on 
SNVs of different allele frequency ranges (Figure 5a) showed the model reaches 
relatively stable performance for SNVs with greater than 1% frequency. 
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Figure 5 RareVar: Performance evaluations and comparisons. a. The precision and 
recall are evaluated at classification probabilities from 0 to 0.95, in steps of 0.05. Points 
with 0.50 probability are highlighted. The classification probability is outputted by the 
machine-learning algorithm, which evaluates the probability of a candidate SNV being a 
true SNV. 0.50 is the threshold. b. The depth is sampled from 10% to 100% of the 
original, in steps of 5%. c. Benchmark performance optimized parameters 
(Supplementary table 6) were applied for VarScan2, Strelka and TVC to compare with 
PSEM and with RareVar. 
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Figure 6 RareVar: comparison of precision at various frequencies. 
44 
2.3.3.2 Effects of Sequencing Depth on the Model Performances 
Another factor affecting variant identification is the sequencing depth. The 
average sequencing depth for the testing set tumor sample (Table 1) was 3,973. In order 
to evaluate the influence of sequencing depth on the precision and recall for the SNVs at 
various allele frequencies, we gradually down-sampled the testing benchmark tumor 
sample sequencing data by randomly selecting a fixed percentage of reads from the 
original sequencing data. The precision is not affected (Figure 6), but the recall steadily 
decreases with reducing average depths for SNVs at all ranges of frequencies (Figure 
5b). It is also obvious that the trend for the decreasing is more severe when the 
sequencing depth is less than 1000x. This result suggests that sequencing depth should 
be pre-determined for detecting SNVs at a specific frequency range. In addition, for the 
variants whose allele frequency is greater than 0.5%, the recall curve reaches a plateau 
when average sequencing depth is greater than 2000x. This suggests that further 
increasing the sequencing depth won’t improve the sensitivity of the detection. 
 
2.3.4 Performance Comparison with Existing Methods 
We compared RareVar with established variant detection tools including 
VarScan2, TVC from Torrent Suite software, and Strelka. Since the default settings for 
these tools aim at SNVs with higher allele frequency, customized parameters were 
selected by optimizing for rare variants (details in Method and Table 5). RareVar was the 
best method in overall performance (Figure 5c and Table 6), with the advantage over the 
second best method, TVC, most evident for 1% and 0.5% frequencies. At 1% allele 
frequency, the precision is similar for both methods, while RareVar achieved 81.2% 
recall, compared with 28.5% for TVC. Even at 0.5% allele frequency, RareVar 
maintained 90.7% precision and 35.6% recall. It is expected that TVC also demonstrates  
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Figure 7 RareVar: comparison of precision and recall for common SNVs. 
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good performance for > 1% since it is specifically designed for Ion Proton technology, by 
using post-alignment correction for homopolymers. Although Strelka achieved 
comparable performance for more frequent SNVs (≥10%) (Figure 7), it showed 
unsatisfactory results for SNVs with allele frequency < 3%. Overall, RareVar shows the 
best performance among all the tools tested, in particular for the SNVs with low allele 
frequencies (0.5%-3%). 
 
2.4 Discussion 
The framework of RareVar provides guidance for low frequent SNV identification 
from both experimental and algorithmic aspects. Many components in the next 
generation sequencing pipeline, including library preparation, target enrichment assay 
and sequencing technology, affect the sensitivity and fidelity of SNV detection. The 
comparison of RareVar with other algorithms underscores the necessity of modeling 
frequency detection limits and the significance of a model tailored for each technology. It 
is impractical to have a universal parameter or threshold setting scheme that fits all 
sequencing platforms and experimental protocols. To solve this problem, we construct a 
benchmark sample containing variants with desired allele frequencies. The distribution of 
the nucleotide mismatch patterns around the positive and negative variant loci in the 
benchmark sample provides a valuable guideline for optimizing the parameter and 
threshold settings during the variant identification process. In addition, the independent 
testing benchmark samples also enables fair evaluation on the performance of the 
detection. 
The two stages in the computational modeling, position-specific error model 
(PSEM) and machine-learning-based recalibration, were designed to take the 
advantages of sequencing signals on the invariant loci, and designed variant loci, 
respectively. The PSEM step intends to model how genomic sequence contexts impact 
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the sequencing error profiles that are associated with the experimental protocol.  The 
derived model serves as an important base for accurately estimating background error 
signal that are specific to any particular nucleotide position. This step is critical in 
improving the detection accuracy of the SNVs with extreme low frequency, as opposed 
to using a universal background error rate for all the genomic loci. 
A machine-learning-based algorithm is applied in the variant recalibration stage, 
in which experiment-related features, such as strand bias and mapping quality, are 
considered. This design effectively avoids using a series of filters that often involves 
multiple ad hoc thresholds. Conceptually, this is similar to the variant recalibration 
strategy used in GATK with two major differences. First, GATK assumes that identified 
variant loci documented in the dbSNP database are likely to be true positive variants. 
This assumption is not valid for cancer somatic mutations, in which most mutation loci 
are random and the allele frequencies in the sample vary. Second, GATK constructed a 
Bayes Gaussian mixture model only based on true positive variant loci while false 
positive loci are difficult to determine without a gold standard dataset. With our strategy, 
however, both true positive and true negative variants are available for the benchmark 
sample. This enables using more sophisticated machine learning algorithm, such as 
random forest model. We demonstrated that variant recalibration step significantly 
increase the specificity of the variant identification, and further improved the overall 
accuracy. 
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Chapter 3. Analyzing Mutational Drift and/or Enrichment in Reprogrammed 
Primary Breast Tumor Cells 
3.1 Introduction 
Reliably detecting low frequency SNVs from NGS sequencing data provides 
great promises for cancer research and clinical applications. Deep sequencing targeted 
regions to measure the low frequency SNVs is a commonly used approach [15, 97, 98]. 
However, NGS sequencing platform artifact level (0.1~1%) puts a barrier in terms of how 
low frequency can be detected. In addition, intratumor heterogeneity is prevalent in 
tumors [99, 100]. Thus directly sequencing bulk tumors might not allow us to detect low-
prevalent subpopulations with actionable mutations. Multiregion sequencing was 
employed to uncover the intratumor heterogeneity by sequencing multiple spatially 
different biopsies and checking the geographically distinct patterns of somatic mutations 
[101]. Yates et al [102] sequenced breast tumor biopsies from multiregion and confirmed 
the importance of considering subclonal structure in breast cancer research and clinical 
trials. Another way of considering subclonal structure is to provide suitable conditions 
and allow the subclones to grow, and thus the minor subpopulations with growth 
advantage may grow and be detectable. Comparing the mutational profiles of cultivated 
tumor cells with that from the original tumor tissue, the mutational drift and/or enrichment 
in cultivated tumor cells could be revealed. These events provide insights about the 
tumor subpopulation evolution as well as clues for cancer treatment. 
To cultivate tumor cells, cell reprogramming was used to induce the tumor tissue 
cells to grow indefinitely in vitro [103]. The reprogramming step cultivates primary tissue 
cells using irradiated mouse embryonic fibroblasts as feeders and media containing 
ROCK inhibitor [104, 105]. To detect somatic mutations from unprocessed primary tumor 
cells and potential mutational drift and/or enrichment from reprogrammed tumor, we 
sequenced DNA samples from the following cell types: patient peripheral blood, 
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unprocessed tumor tissue and tumor adjacent normal tissue, reprogrammed tumor cells 
and tumor adjacent normal cells.  The mutations from peripheral blood represent the 
germline mutational landscape and thus can be used to determine somatic mutations in 
tumor samples. In the absence of blood samples, unprocessed tumor adjacent normal 
tissue cells are used to derive germline mutations. The unprocessed tumor tissue cells 
contain the somatic mutations from multiple tumor cell subpopulations, in which some 
populations may harbor malignant mutations that bear growth advantage over others. 
However, if sequencing the bulk tumor, some of the minor tumor subpopulations with 
unique mutations may not be detectable. We hypothesized that the reprogrammed cells 
allow the expansion of the minor population of tumor cells with growth advantage. Thus, 
by comparing primary tumor cell mutational profile with that from its reprogrammed 
counterpart, we can identify mutational drift and/or enrichment. The reprogrammed cells 
may contain mouse cells, which could be mistaken as human somatic mutations if not 
carefully characterized. We applied bioinformatics approaches to filter sequencing reads 
likely from mouse cells. 
 
3.2 Materials and Methods 
3.2.1 Materials and Sequencing 
Blood, fresh adjacent normal and tumor tissues from 5 patients were obtained 
from Indiana University Simon Cancer Center (IUSCC) Tissue Bank. Table 7 
summarized the number of samples sequenced from each type, the patients are 
grouped as ‘A’ and ‘B’ depending on the available sample types. Among these patients 
1402-17 is unique in that she had different types of breast tumors.  
The collaborators prepared the reprogrammed tumor cells. Briefly, the tissue 
samples from IUSCC were split into two. One part was frozen and the other part was 
used to cultivate primary cells using irradiated mouse embryonic fibroblasts as feeders 
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and media containing ROCK inhibitor [105]. Jam-A/EpCAM were used to remove mouse 
fibroblasts. Jam-A+/EpCAM+ cells were sorted by flow cytometry and thus mouse 
fibroblasts were removed since they did not stain for these markers. 
All samples were sequenced with Ion Proton. The sequencing library preparation 
and sequencing data alignment as well as post-alignment filtering were the same as 
described in Chapter 2 section 2.2.2. 
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Table 7 Summary of breast tumor samples and types sequenced.  
  Unprocessed Reprogrammed  
Patient 
ID Group Blood / Normal Tumor Normal Cell Tumor Cell 
1406-26 B Adjacent Normal Yes Yes Yes 
1411-04 B Adjacent Normal Yes Yes Yes 
1310-33 A Blood Yes  Yes 
DCIS A Blood Yes  Yes 
LCIS A Yes  Yes 
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3.2.2 In-silico Characterizing and Filtering Sequencing Reads Originating from 
Mouse 
To characterize the degree of contamination from mouse cells, we first applied in 
silico PCR to tabulate the percentage of amplicon primer pairs that can also specifically 
pull down sequences from mouse genome. The in silico PCR tool from UCSC genome 
browser [106] is used to search over ~16,000 amplicon primer pairs from the Ion 
AmpliSeq Comprehensive Cancer panel. The default parameters for in silico PCR tool in 
UCSC genome browser were used, which required 15bp perfect match for both 5’ and 3’ 
primers and also maximum 4000bp amplified region.  We found that 235 primer pairs 
can also pull down mouse genome sequences, which is 1.47% of all amplicons.  
Despite the low percentage of amplicon primer pairs that may introduce mouse 
DNA contamination, it is still necessary to consider the possibility that the primer pairs 
may have some level of random pairing which may potentially pull down mouse genome 
sequences. However, the combinatory search space is huge (16,000 * 16,000), thus we 
explored several methods of finding mouse genome reads based on comparative 
alignment between the mouse and human genome. 
The sequencing reads derived for cultured reprogrammed cells were mapped 
both to the human genome (genome build hg19) and the mouse genome (genome build 
mm10) [107] using TMAP from Torrent Suite software. To distinguish reads from mouse 
rather than human, we explored 3 strategies to filter the sequencing data, (1) ‘no mouse’ 
which removes reads that can be aligned to the mouse genome with mapping quality 
greater than 20, (2) ‘MAPQ’ which removes reads that have a larger mapping qualities 
when mapped to the mouse genome than the human genome, (3) ‘longer match’ which 
removes reads that have a larger total number of aligned bases to the mouse genome 
than the human genome.  
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To compare the performances of the filtering methods, different strategies were 
designed for the two patient groups due to the different availability of sample types in the 
two groups. For group A, to evaluate the consequences of false positive filtering, we 
checked the agreement of SNVs between unprocessed tumor and after applying mouse 
read filtering. Since there should be no mouse cell contamination in unprocessed 
tumors, any reads removed are false positive mouse reads. For group B, to evaluate the 
efficiency of different methods in removing reads from mouse cells, we checked the 
agreement of SNVs between unprocessed normal tissues and reprogrammed normal 
cells. Since there should be no new mutations or small number of mutations potentially 
induced by reprogramming process in normal cells, any new SNVs from normal cells 
compared with unprocessed normal tissues were considered as false positive SNVs due 
to contamination from mouse cells. We calculated recall, precision, and F1 score as 
described in section 3.2.3.  
 
3.2.3 Detecting Somatic SNVs with RareVar 
SNV detection was done with RareVar described in chapter 2, to effectively deal 
with diluted SNV signals from low-prevalence tumor subpopulations. For each patient, all 
types of samples independently went through the Bayes factor based candidate SNV 
identification and machine-learning based recalibration in RareVar framework to derive 
SNVs, then we applied a series of filters and statistical tests to determine somatic SNVs. 
Step 1: filtered candidate somatic SNVs by only including SNVs (1) not in potentially 
mouse contaminated amplicons, (2) RareVar detected those SNVs in either tumor tissue 
or tumor cells and the allele frequencies are larger than those in the germline sample, 
(3) depths on SNV loci in tumor tissue and tumor cells are greater than 100 and (4) 
maximum of allele frequencies from tumor tissue and tumor cells are at least 2-fold of 
the allele frequencies from germline sample. Step 2: for SNVs detected in both tumor 
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tissue and tumor cells, a binomial test (p value threshold 0.01, single sided test) was first 
used to check if the allele frequencies are significantly larger than those in germline 
sample. Then only the ones showing larger frequencies were kept and went through a 
second binomial test to see if the allele frequencies in tumor tissue are different from 
those in tumor cells. If allele frequencies are significantly (p value threshold 0.01, single 
sided test) greater in tumor cells, then those SNVs potentially are from enriched tumor 
subpopulations in tumor cells. If the allele frequencies in tumor cells are smaller or 
similar, then the prevalence of these host tumor subpopulations possibly did not change. 
Step 3: for SNVs only detected in tumor tissue by RareVar, we first used binomial test to 
make sure the allele frequencies were greater than those in the germline sample, then 
checked whether there are also reads supporting those SNVs in tumor cells. If there are, 
it is an indicator of the host subpopulation shrinkage (the percentage in tumor cells is 
smaller than in tumor tissue) and also increases our confidence that those are true 
somatic SNVs rather than sequencing artifacts. Step 4:  for SNVs only detected in tumor 
cells by RareVar, we first used binomial test to make sure the allele frequencies were 
greater than those in the germline sample, then checked whether there are also reads 
supporting those SNVs in tumor tissue. If there are, it is an indicator of the host 
subpopulation enrichment and also increased our confidence that those are true new 
somatic SNVs rather than sequencing artifacts. 
 
3.3 Results 
3.3.1 Removing Contaminating Reads from Residual Mouse Cells 
We first explored the percentage of reads removed by all methods described in 
section 4.3.1. Taking 1406-26 tumor cell sample as an example, ~32% reads were 
removed by ‘no mouse’ method while only 1~2% reads were removed by ‘MAPQ’ or 
‘longer match’ method. This result agrees with the speculation that ‘no mouse’ method 
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tends to remove many reads from human and mouse homologous regions, since the 
protein-coding regions of human and mouse genomes are on average 85 percent 
identical [109]. Thus, we further explored the effectiveness of the other two methods by 
comparing the consistency of detected SNVs from tumor/normal cell with unprocessed 
tumor/normal tissue samples. 
We checked the effect of falsely removing reads from human on SNV calling in 
group A. The key values are the number of SNVs after read filtering that overlapped with 
unfiltered samples, referred as ‘Overlapped with UP Tumor’ in Table 8A. For all three 
samples, ‘longer match’ and ‘MAPQ’ performed similarly. ‘MAPQ’ correctly recovered 1 
more SNV from 1310-33 while ‘longer match’ correctly recovered 4 more SNVs from 
DCIS (Table 8A). When visually comparing the performances of the two methods using 
the recall, precision and F1 score measures, no visible differences could be observed 
except for the recall for DCIS (Figure 8).   
We checked the effect of failing to remove reads from mouse cells on SNV 
calling in group B. The key values are the number of SNVs after read filtering that 
overlapped with unprocessed normal tissue samples, referred as ‘Overlapped with UP 
Normal’ in Table 8B. The numbers of overlapped SNVs were slightly higher in ‘longer 
match’ for both samples. Besides, ‘MAPQ’ filtered data had more SNVs identified, 57 
more in 1406-26 and 804 more in 1411-04. We hypothesized there should be no or only 
small number of new SNVs in reprogrammed normal cells, thus the ‘MAPQ’ method is 
considered to be less efficient in removing reads from mouse cells. When visually 
comparing the performances of the two methods using the recall, precision and F1 score 
measures, visible differences could be observed for the recall and F1 score for both 
samples in group B (Figure 8).  Thus, ‘longer match’ was used as the read filtering 
method. 
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Table 8 Comparing methods for removing reads from mouse cells. Samples with blood, unprocessed tumor tissue and 
reprogrammed tumor cells are grouped in A. Samples with unprocessed normal and tumor tissues, as well as reprogrammed normal 
and tumor cells are grouped in B. UP Tumor: unprocessed tumor. UP Normal: unprocessed adjacent normal tissue. Normal Cell: 
reprogrammed normal cells. For cells with a single number, that number is the number of SNVs detected. For cells with 2 numbers, 
the configuration is explained in the third point by the end of table B.  
A 
        MAPQ Filter1 Longer Match Filter2 
Sample UP Tumor Filtered UP Tumor / Overlapped with UP Tumor 
Filtered UP Tumor / 
Overlapped with UP Tumor 
1310-33 1143 1143 / 11423 1141 / 1141 
DCIS 1150 1145 / 1145 1150 / 1149 
LCIS 1139 1141 / 1138 1141 / 1138 
       
       B 
  MAPQ Filter1 Longer Match Filter2 
Sample UP Normal Filtered Normal Cell / Overlapped with UP Normal 
Filtered Normal Cell / 
Overlapped with UP Normal 
1406-26 1117 1192 / 1076 1135 / 1080 
1411-04 1123 1977 / 1076 1173 / 1077 
1: MAPQ Filter - remove reads that have a larger mapping quality when mapped to mouse genome. 
2: Longer Match Filter - remove reads that have a larger total number of mapped bases when mapped to mouse genome. 
3: In this example, 1143 is the number of SNVs detected in filtered UP tumor sample, while 1142 is the number of SNVs from filtered 
UP tumor sample that overlapped with UP tumor sample. The other cells with the format ‘number 1’ / ‘number 2’ could also be 
explained by checking their column names. 
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 Figure 8 Comparing methods for removing reads from mouse cells. 
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3.3.2 Summary of Identified SNVs and Their Functional Implications 
We derived the somatic SNVs based on the 4 steps applied to RareVar results 
described in section 3.2.3. A summary of the SNVs of different potential functional 
groups was list in Table 9. For all somatic candidate SNVs, they are mostly identified in 
either tumor tissue or tumor cells but not both. Number of SNVs possibly going through 
somatic enrichment is more than those of somatic shrinkage.  
For every patient, we selected candidate SNVs for further examination. 
Reprogrammed tumor cells from patient 1310-33 showed splice site mutation of ETV1 
oncogene [110-114], and both tumor tissue and cells showed a stop-gain mutation from 
tumor metastasis-associated gene MYH9 [115, 116]. In tumor cells from a patient (1402-
17) with lobular carcinoma in situ (LCIS) in her left breast, we detected PI3KCA H1047R 
mutation, a common mutation found in many cancers [117-122]. In this tumor, we also 
detected R554C mutation of FOXO1, a context-dependent tumor suppressor or 
oncogene [123-128]. This is a novel mutation yet to be reported in any cancer. This 
patient had invasive carcinoma with ductal carcinoma in situ (DCIS) in her right breast. 
This tumor had multiple mutations in PIK3R1 gene (L7R, L100R, L70R, and L370R). 
Although PI3KR1 mutations are very common in cancer [129-132], these specific 
mutations have not been reported (as per cBioportal [133, 134]). Tumor cells from 
patient 1406-26 were detected to have a novel nonsynonymous SNV in FZR1 gene 
(N315S, N404S), which is a candidate CDK4/6-cyclin D substrate [135]. Tumor from 
patient 1411-04) showed mutation in the epigenetic regulator DAXX [136-139]. R371W 
mutation of DAXX has previously been reported in two cases of AML [140].  
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Table 9 Summary of detected somatic SNVs in breast tumor samples. 
RareVar SNV Prediction Alternative AF3 
Comparison 
Possible 
Event4 
Number of Somatic SNVs 
UP Tumor1 Tumor Cell2 1310-33 DCIS LCIS 1406-26 1411-04 
Yes Yes Higher in Tumor Cells 
Somatic SNV 
Enrichment 5 0 0 0 0 
Yes Yes Lower in Tumor Cells Somatic SNV  0 1 0 0 0 
Yes Yes Similar Somatic SNV  3 0 0 0 0 
Yes No Low in Tumor Cells 
Somatic 
Shrinkage 3 10 2 4 2 
Yes No 0 in Tumor Cell Somatic in Tissue 3 4 3 5 3 
No Yes Low in UP Tumor 
Somatic SNV 
Enrichment 9 7 102 4 5 
No Yes 0 in UP Tumor New Somatic SNV in Cells 9 6 21 7 3 
1: UP Tumor means unprocessed tumor. 
2: Tumor cell means reprogrammed tumor cells. 
3: AF: allele frequency. Comparing the allele frequencies in tumor tissue and tumor cells. 
4: Biological events that possibly result in the observed allele frequency change. 
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3.4 Discussion 
From experiment design side, the technique adapted in this study of sequencing 
unprocessed tumor and cultured cells from tumors will help to detect novel actionable 
mutations, which are otherwise missed by sequencing only bulk tumors. Variant caller 
designed specifically for sensitive low frequency mutation calling greatly facilitated the 
exploration of previously unknown genetic territories. Despite the novel findings, 
subsequent validation and functional characterization are indispensible to link SNVs to 
the functional disruption and thus uncover new drug targets. 
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Chapter 4. Statistical Modeling for Ion Proton Sequencing Platform Genomic 
Sequence Context Dependent Error 
4.1 Introduction 
In chapter 2, the RareVar framework for low-frequency single nucleotide variant 
detection was introduced. In RareVar, position specific error model (PSEM) using 
genome sequence context features is a key step. It is indispensable for determining 
lowest frequency detection limit as well as identifying candidate SNVs for downstream 
sequencing quality based candidate recalibration. Poisson distribution, a popular choice 
of distribution in modeling count date, was implemented under generalized linear model 
framework. However, the potential to improve PSEM performances on SNVs with close 
to sequencing error rates by implementing more sophisticated statistical distributions 
remains to be explored. In this chapter, we explored what distributions fit the DNA-Seq 
erroneous read count modeling as well as the possibility of improved position specific 
error rate prediction for higher precision and recall on SNVs down to 0.5% frequency. 
We reused the training and testing benchmark data sets sequenced with Ion Proton 
platform from chapter 2. 
 
4.2 Materials and Methods 
 The focus of this chapter is to explore which statistical distribution fits the next 
generation sequencing error count data better. The general workflow for position specific 
error modeling using different distributions is described in Figure 9. In the training phase, 
starting from training benchmark normal sample invariant loci, the genome context 
features are extracted and fed to generalized linear models based on 4 candidate 
distributions. The genome context extraction and the fitted generalized linear models 
constitute the position specific error model. In the testing phase, all loci in the testing 
benchmark paired normal and tumor samples go through the position specific error 
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model and the candidate SNVs significantly different from fitted sequencing errors are 
generated. The following sections described in details the benchmarks and the 
configurations for generalized linear models based on different statistical distributions. 
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Figure 9 Diagram of the position specific error model using different statistical 
distributions. The dashed boxes highlighted the training data and the trained model. 
GLM: generalized linear model. NB: negative binomial. ZIP: zero-inflated Poisson. ZINB: 
zero-inflated negative binomial. 
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4.2.1 Benchmark Datasets 
The Ion Proton training and testing benchmark datasets were generated as 
described in chapter 2 section 2.2.1.  
 
4.2.2 Identifying Distribution Form for Sequencing Error Modeling 
To model error rate based on count data, the 3 most common distribution 
choices are binomial, Poisson and negative binomial distributions. We applied a 
graphical exploratory plot – distplot [141-143] on the model response – number of reads 
containing non-reference bases – to get visual intuition about the overall fit of response 
data on different distributions. Intuitively, if an assumed distribution fits the data well, the 
data points should follow a straight line determined by the distribution metameters [141-
143, 145]. The metameter of a discrete distribute equals a linear function of the count 
data (k), with the slope and intercept being the functions of distribution parameters. 
Under the context of sequencing error modeling, the count data k is observed number of 
reads supporting an alternative allele at a specific genomic locus.  
Poisson distribution is taken as an example here to illustrate the form of the 
metameters. Assume a Poisson distribution with some fixed parameter mean λ, the 
observed frequency 𝑛𝑛𝑘𝑘 for a value k equals the expected frequency 𝑆𝑆 ∗ 𝑝𝑝𝑘𝑘, where 𝑆𝑆 is 
the total number of data points and 𝑝𝑝𝑘𝑘 is the probability of observing k. Thus, setting 
𝑛𝑛𝑘𝑘 = 𝑆𝑆𝑝𝑝𝑘𝑘 = 𝑆𝑆𝑒𝑒−𝜆𝜆𝜆𝜆𝑘𝑘/𝑘𝑘!, and taking logs of both sides gives 
 
 log(𝑛𝑛𝑘𝑘) = log(𝑆𝑆) − 𝜆𝜆 + 𝑘𝑘𝑙𝑙𝑃𝑃𝑙𝑙𝜆𝜆 − 𝑙𝑙𝑃𝑃𝑙𝑙𝑘𝑘! (6) 
 
This can be rearranged to a linear equation in k,  
 
∅(𝑛𝑛𝑘𝑘) = 𝑙𝑙𝑃𝑃𝑙𝑙 �𝑘𝑘!𝑛𝑛𝑘𝑘𝑆𝑆 � = −𝜆𝜆 + (𝑙𝑙𝑃𝑃𝑙𝑙𝜆𝜆)𝑘𝑘 (7) 
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The left side of equation is called the count metameter, and denoted ∅(𝑛𝑛𝑘𝑘). Hence, 
plotting ∅(𝑛𝑛𝑘𝑘) against k should give a straight line of the form ∅(𝑛𝑛𝑘𝑘) = 𝑓𝑓 + 𝑏𝑏𝑘𝑘 with slope 
𝑙𝑙𝑃𝑃𝑙𝑙𝜆𝜆 and intercept −𝜆𝜆, when the observed frequencies follow a Poisson distribution. The 
metameters slopes and intercepts for binomial and negative binomial distributions are 
summarized in Table 10.  
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Table 10 Distplot parameters for three discrete distributions. In each case the count 
metameter is plotted against k, yielding a straight line when the data follow the given 
distribution. k is the count data to be checked for appropriate distributions.  
Distribution Binomial Poisson Negative Binomial 
Probability 
Function, p(k) �
𝑛𝑛
𝑘𝑘
�𝑝𝑝𝑘𝑘(1 − 𝑝𝑝)𝑛𝑛−𝑘𝑘 𝑒𝑒−𝜆𝜆𝜆𝜆𝑘𝑘/𝑘𝑘! �𝑛𝑛 + 𝑘𝑘 − 1
𝑘𝑘
�𝑝𝑝𝑛𝑛(1 − 𝑝𝑝)𝑘𝑘 
Count 
Metameter, 
∅(nk) 𝑙𝑙𝑃𝑃𝑙𝑙 �𝑛𝑛𝑘𝑘/𝑆𝑆�𝑛𝑛𝑘𝑘�� log (𝑘𝑘!𝑛𝑛𝑘𝑘/𝑆𝑆) 𝑙𝑙𝑃𝑃𝑙𝑙 �𝑛𝑛𝑘𝑘/𝑆𝑆�𝑛𝑛 + 𝑘𝑘 − 1𝑘𝑘 �� 
Theoretical 
Slope log �𝑝𝑝 1 − 𝑝𝑝� � log (𝜆𝜆) log (1 − 𝑝𝑝) 
Theoretical 
Intercept 𝑛𝑛𝑙𝑙𝑃𝑃𝑙𝑙(1 − 𝑝𝑝) −𝜆𝜆 nlog (𝑝𝑝) 
Table adapted from Hoaglin and Tukey (1985) [145], Table 9-15. 
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4.2.3 Generalized Linear Models 
The details of the 9 genomic sequence contexts considered in generalized linear 
models were summarized in Table 2. These 9 features are the covariates included in the 
GLMs.  
The Poisson distribution GLM specification remains the same as described in 
chapter 2 section 2.2.2. For the purpose of comparing with other distributions, the 
equation and variable descriptions are included below. The Poisson GLM for erroneous 
sequencing read counts with log link function is expressed in equation (8), where 𝑆𝑆𝑠𝑠,𝑏𝑏,𝑙𝑙 is 
the observed number of erroneous reads for strand s (forward or reverse) with 
alternative base b (three possible values other than the reference) at location l, 𝜆𝜆𝑠𝑠,𝑏𝑏,𝑙𝑙 
represents the expected mean for 𝑆𝑆𝑠𝑠,𝑏𝑏,𝑙𝑙, 𝒄𝒄𝑠𝑠,𝑏𝑏,𝑙𝑙 is the vector of genomic sequence context 
covariates, and 𝜷𝜷 is the vector of fitted coefficients. The sequencing depth for strand s at 
location l is treated as the offset. 
 
 log�𝜆𝜆𝑠𝑠,𝑏𝑏,𝑙𝑙� = log �𝐸𝐸�𝑆𝑆𝑠𝑠,𝑏𝑏,𝑙𝑙�𝒄𝒄𝑠𝑠,𝑏𝑏,𝑙𝑙�� = log�𝑑𝑑𝑠𝑠,𝑙𝑙� + 𝜷𝜷′𝒄𝒄𝑠𝑠,𝑏𝑏,𝑙𝑙 (8) 
 
The negative binomial distribution GLM with log link function can be expressed in 
equation (9), where 𝜇𝜇𝑠𝑠,𝑏𝑏,𝑙𝑙 represents the expected mean for 𝑆𝑆𝑠𝑠,𝑏𝑏,𝑙𝑙 and 𝜃𝜃 is the dispersion 
parameter (the shape parameter of the gamma mixing distribution). The mean 
𝐸𝐸�𝑆𝑆𝑠𝑠,𝑏𝑏,𝑙𝑙� = 𝜇𝜇𝑠𝑠,𝑏𝑏,𝑙𝑙 and variance 𝑆𝑆𝑉𝑉𝑉𝑉�𝑆𝑆𝑠𝑠,𝑏𝑏,𝑙𝑙� = 𝜇𝜇𝑠𝑠,𝑏𝑏,𝑙𝑙 + 𝜃𝜃𝜇𝜇𝑠𝑠,𝑏𝑏,𝑙𝑙  2  can be estimated from GLM 
shown below. 
 
 log�𝜇𝜇𝑠𝑠,𝑏𝑏,𝑙𝑙� = log �𝐸𝐸�𝑆𝑆𝑠𝑠,𝑏𝑏,𝑙𝑙�𝒄𝒄𝑠𝑠,𝑏𝑏,𝑙𝑙�� = log�𝑑𝑑𝑠𝑠,𝑙𝑙� + 𝜷𝜷′𝒄𝒄𝑠𝑠,𝑏𝑏,𝑙𝑙 (9) 
 
The zero-inflated Poisson distribution can be written as: 
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 𝑃𝑃�𝑆𝑆𝑠𝑠,𝑏𝑏,𝑙𝑙 = 𝑛𝑛𝑠𝑠,𝑏𝑏,𝑙𝑙|𝜋𝜋𝑠𝑠,𝑏𝑏,𝑙𝑙 ,𝜆𝜆𝑠𝑠,𝑏𝑏,𝑙𝑙 ,𝜃𝜃�
= {𝜋𝜋𝑠𝑠,𝑏𝑏,𝑙𝑙 + �1 − 𝜋𝜋𝑠𝑠,𝑏𝑏,𝑙𝑙�𝑃𝑃𝑃𝑃𝑃𝑃𝑠𝑠�𝜆𝜆𝑠𝑠,𝑏𝑏,𝑙𝑙; 0�              𝑃𝑃𝑓𝑓  𝑛𝑛𝑠𝑠,𝑏𝑏,𝑙𝑙 = 0
�1 − 𝜋𝜋𝑠𝑠,𝑏𝑏,𝑙𝑙�𝑃𝑃𝑃𝑃𝑃𝑃𝑠𝑠�𝜆𝜆𝑠𝑠,𝑏𝑏,𝑙𝑙;𝑛𝑛𝑠𝑠,𝑏𝑏,𝑙𝑙�                      𝑃𝑃𝑓𝑓  𝑛𝑛𝑠𝑠,𝑏𝑏,𝑙𝑙 > 0 (10) 
 
Parameters of the zero-inflated Poisson distribution in equation (10) can be 
estimated by generalized linear model as shown in equation (11), where 𝒛𝒛𝑠𝑠,𝑏𝑏,𝑙𝑙  is the 
vector of genomic sequence context covariates for the zero part, and 𝜸𝜸 is the vector of 
fitted coefficients. 
  logit� 𝜋𝜋𝑠𝑠,𝑏𝑏,𝑙𝑙1 − 𝜋𝜋𝑠𝑠,𝑏𝑏,𝑙𝑙� = 𝜸𝜸′𝒛𝒛𝑠𝑠,𝑏𝑏,𝑙𝑙 (11)  log�𝜆𝜆𝑠𝑠,𝑏𝑏,𝑙𝑙� = 𝜷𝜷′𝒄𝒄𝑠𝑠,𝑏𝑏,𝑙𝑙 
 
The zero-inflated negative binomial distribution can be written as: 
 
 𝑃𝑃�𝑆𝑆𝑠𝑠,𝑏𝑏,𝑙𝑙 = 𝑛𝑛𝑠𝑠,𝑏𝑏,𝑙𝑙|𝒄𝒄𝑠𝑠,𝑏𝑏,𝑙𝑙 ,𝒛𝒛𝑠𝑠,𝑏𝑏,𝑙𝑙�
= {𝜋𝜋𝑠𝑠,𝑏𝑏,𝑙𝑙 + �1 − 𝜋𝜋𝑠𝑠,𝑏𝑏,𝑙𝑙�𝑆𝑆𝐵𝐵�𝜇𝜇𝑠𝑠,𝑏𝑏,𝑙𝑙 ,𝜃𝜃; 0�           𝑃𝑃𝑓𝑓  𝑛𝑛𝑠𝑠,𝑏𝑏,𝑙𝑙 = 0
�1 − 𝜋𝜋𝑠𝑠,𝑏𝑏,𝑙𝑙�𝑆𝑆𝐵𝐵�𝜇𝜇𝑠𝑠,𝑏𝑏,𝑙𝑙 ,𝜃𝜃;𝑛𝑛𝑠𝑠,𝑏𝑏,𝑙𝑙�                   𝑃𝑃𝑓𝑓  𝑛𝑛𝑠𝑠,𝑏𝑏,𝑙𝑙 > 0 (12) 
 
Parameters of the zero-inflated negative binomial distribution in equation (12) 
can be estimated by generalized linear model as shown in equation (13). 
  logit� 𝜋𝜋𝑠𝑠,𝑏𝑏,𝑙𝑙1 − 𝜋𝜋𝑠𝑠,𝑏𝑏,𝑙𝑙� = 𝜸𝜸′𝒛𝒛𝑠𝑠,𝑏𝑏,𝑙𝑙 (13)  log�𝜇𝜇𝑠𝑠,𝑏𝑏,𝑙𝑙� = 𝜷𝜷′𝒄𝒄𝑠𝑠,𝑏𝑏,𝑙𝑙 
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4.2.4 Variant Identification 
In chapter 2, the variant identification is done using Bayes factor by calculating 
the likelihood ratio of two models: ME, the ‘sequencing error distribution’ model and MV, 
the ‘targeted lowest identifiable frequency distribution’ model. Thus a predefined 
‘targeted lowest frequency’ is needed. Here we used a hypothesis testing approach, to 
call candidate SNVs if the data are not from the sequencing error distribution. 
Specifically, a location with a certain alternative base is called as a candidate SNV if the 
numbers of reads from both strands are significantly greater than the predicted error 
rates. The p values were corrected using Benjamini–Hochberg procedure [146]. The 
corrected p value cut-off is 0.01. 
 
4.2.5 Performance Evaluation Measurements 
Precision and recall are defined as equations (4) and (5) in chapter 2. F1 score is 
defined below.  
 
 
𝐵𝐵1 = 2 ∗ 𝑝𝑝𝑃𝑃𝑒𝑒𝑐𝑐𝑃𝑃𝑠𝑠𝑃𝑃𝑃𝑃𝑛𝑛 ∗ 𝑃𝑃𝑒𝑒𝑐𝑐𝑓𝑓𝑙𝑙𝑙𝑙
𝑝𝑝𝑃𝑃𝑒𝑒𝑐𝑐𝑃𝑃𝑠𝑠𝑃𝑃𝑃𝑃𝑛𝑛 + 𝑃𝑃𝑒𝑒𝑐𝑐𝑓𝑓𝑙𝑙𝑙𝑙 (14) 
 
For Ion Proton dataset, same as chapter 2, only loci with at least 5 reads supporting 
alternative base are included in the evaluation. 
 
4.3 Results 
In the Result section, we first show the intuitions derived from visualization 
inspection for diagnosing the distribution form of sequencing error modeling. Then 
utilizing statistical testing of goodness-of-fit on different distributions, we selected the 
candidate distributions more appropriate for fitting the sequencing error count data. Then 
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we showed the performance of position specific error model using different distributions 
on identifying candidate SNVs, highlighted the merits of choosing appropriate 
distributions. 
 
4.3.1 Candidate Statistical Distributions Selection 
If the count data follow a given discrete distribution, then the visualization from 
distplot [141-143] shows the metameter is a linear function of all observed values. We 
plotted the number of reads containing non-reference alleles from all targeted region loci 
against binomial, Poisson and negative binomial distributions. As shown in Figure 10, 
the obvious curve for binomial distribution plot indicates the data do not follow binomial 
distribution. The plots for Poisson and negative binomial distributions show better 
agreement with the straight line although both curves deviate more from the straight line 
when the x-axis approaches 0. Further, if for each locus, the observed number of reads 
supporting each possible substitution type is called ‘error instance’. Then tabulating the 
percentages of zeros in all the error instances within the target regions, we got 85% from 
Ion Proton training dataset. Thus zero-inflated models should be considered. In the 
modeling step, we included Poisson, negative binomial and their zero-inflated 
counterparts (zero-inflated Poisson [147] and zero-inflated negative binomial [148]) as 
the candidate distributions under generalized linear model framework. 
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Figure 10 Distplot on binomial, Poisson and negative binomial distributions. The y-axis 
is the distribution metameter calculated by the method distplot used. The open points 
show the observed count metameters; the filled points show the confidence interval 
centers and the dashed lines show the confidence intervals for each point. 95% 
confidence interval is used. 
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4.3.2 Comparing the Goodness-of-Fit of Different Distributions 
9 genomic sequence context covariates, totaling 24 degrees of freedom, were 
included in the generalized linear models (section 3.2.2 and Table 2). Since zero-inflated 
Poisson and zero-inflated negative binomial generalized linear models require covariates 
for both the ‘zero’ and ‘count’ parts, the same covariates were provided for both, 
resulting in doubled degrees of freedom of those included in Poisson and negative 
binomial generalized linear models. 
To compare the goodness-of-fit of models based on different distributions, we 
used Vuong’s non-nested hypothesis test [149]. BIC-corrected Vuong z-statistic [150] 
was used to impose stronger penalty on additional parameters. The pairwise comparison 
results are summarized in Table 11. Poisson distribution GLM is treated as the reference 
distribution to compare to, given its simple configuration. As expected, negative binomial 
GLM is superior to Poisson GLM, since negative binomial distribution models dispersion 
of the data, and this is also supported by dispersion test [151] (z = 68.5881, p value < 
2.2e-16). The necessity of modeling zero-inflation is supported by the Vuong’s test 
comparing zero-inflated Poisson with Poisson GLM. When comparing zero-inflated 
Poisson with negative binomial, negative binomial distribution fits the data better. 
However, it is worth noting the evidence of superiority – the absolute value of BIC-
corrected Vuong z-statistic – is much smaller than the other tests. The merit of 
considering both dispersion and zero-inflation is further emphasized by the comparisons 
of zero-inflated Poisson with zero-inflated negative binomial and negative binomial with 
zero-inflated negative binomial. In conclusion, based on Vuong’s test, for Ion Proton 
sequencing dataset, the most appropriate distribution for modeling DNA sequencing 
error read counts is zero-inflated negative binomial distribution.  
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Table 11 Vuong’s non-nested tests for Ion Proton training data. NB: negative 
binomial. ZIP: zero-inflated Poisson. ZINB: zero-inflated negative binomial. ‘>’ 
means a better fit of the left model.  
 
Model 1 
 
Model 2 
Vuong z-statistic 
BIC-corrected 
 
Hypothesis 
 
P value 
  Poisson NB           -122.67    model2 > model1 < 2.22e-16 
Poisson ZIP -143.73 model2 > model1 < 2.22e-16 
NB ZIP 36.81 model1 > model2 < 2.22e-16 
ZIP ZINB -92.16 model2 > model1 < 2.22e-16 
NB ZINB -119.51 model2 > model1 < 2.22e-16 
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4.3.3 Performance Evaluation on Ion Proton Testing Benchmark 
In the previous section, we used Vuong’s test to establish that in modeling DNA 
sequencing error count data, the advantage of zero-inflated negative binomial 
distribution in fitting the data is statistically significant. In this section, we explored 
whether such statistical advantage could also be reflected in the ability to identify low-
frequency SNVs. We first evaluated the overall precision and recall values of all 
distributions on the test benchmark. From Table 12, it is observed the Poisson GLM 
achieves the highest recall while zero-inflated negative binomial GLM has the highest 
precision. F1 score, the harmonic mean of precision and recall, is used to evaluate the 
overall performance. The conclusion from F1 score is consistent with that of Vuong’s 
test, with zero-inflated negative binomial performs the best and is followed by negative 
binomial, zero-inflated Poisson and Poisson GLM. However, the precision values listed 
in Table 12 are lower than the ones reported previously [15, 72, 73]. There are 2 major 
reasons: 1. the Ion Proton test benchmark dataset is designed to enrich with low-
frequency SNVs, with 68.9% of all SNVs of allele frequency <= 3%, in which 17.3% at 
0.5% frequency and 19.8% at 1% frequency. Whereas the majority of previous studies 
focused on SNVs of >= 5% allele frequency; 2. one popular paradigm of SNV calling is a 
two-step procedure, first generating SNV candidates and then applying different 
methods to recalibrate the SNV call, for example filters and machine-learning based 
recalibration. The PSEM aims to efficiently recover high quality SNV candidates to 
facilitate the downstream candidate recalibration step, thus it is only fair to compare the 
performance of PSEM with other candidate generating methods.  
Then we evaluated the effect of different variant identification methods. We 
compared the hypothesis-testing based variant identification with the Bayes factor 
approach used in chapter 2 (Poi_BF in Table 12). The overall F1 score for Bayes factor 
approach Poi_BF is between Poisson distribution and zero-inflated Poisson distribution, 
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and is notably inferior to negative binomial distribution and zero-inflated negative 
binomial distribution. In addition, hypothesis-testing approach does not require an 
additional parameter specifying the targeted lowest frequency required by Bayes factor 
approach. Thus with more appropriate distribution, not only higher performances but 
also a method with less additional constrains can be achieved. The result from 
VarScan2 before applying sequencing quality filters was included in Table 12. It is 
evident that except for Poisson GLM with hypothesis testing and Poisson GLM with 
Bayes factor, the other methods outperformed VarScan2 in both recall and precision. 
Therefore, choosing appropriate statistical modeling method enables us to recover more 
true SNVs without any loss of precision in candidate generating step.   
Next, for all distributions, we explored the performance profiles on different allele 
frequencies. As shown in Figure 11, the clearly layered F1 score levels clearly show that 
SNVs of lower allele frequencies are more difficult to identify, no matter what 
distributions were used. In addition, the significant separation of 0.5% from the other 
allele frequencies indicate the detection limit is around 0.5% under current sequencing 
platform and depth. Meanwhile, the power of appropriate modeling is evident when 
comparing the performances of all distributions on SNVs of 0.5% allele frequency. 
Relative to Poisson GLM, considering either zero-inflation or dispersion boosted the F1 
score by about 0.2 at 0.5%, while considering both by zero-inflated negative binomial 
further increased F1 score by about 0.1. Interestingly, compared with the second best 
model – negative binomial GLM, both precision and recall increased in zero-inflated 
negative binomial GLM, which pinpoints the necessity of modeling zero-inflation to 
derive more accurate error rates estimation. Furthermore, for SNVs with allele frequency 
greater than 1%, the average recall is 97.5% with 82.3% average precision for zero-
inflated negative binomial GLM. Comparing the effect of different variant identification 
approaches, we can see although Poisson GLM performed better with Bayes factor than 
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with hypothesis testing, the differences in performances on less than 3% allele 
frequencies are evident compared with the most appropriate distribution zero-inflated 
negative binomial. To summarize, the performance evaluation results on low-frequency 
SNV identification also support the conclusion from Vuong’s non-nested test, with zero-
inflated negative binomial being the most appropriate model. Further, the necessity of 
modeling both dispersion and zero-inflation is exemplified by the much-elevated 
performance at close to sequencing error rate allele frequency, which is important for 
pushing down the detection limit of low-frequency SNV callers. 
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Table 12 Overall performance comparisons on Ion Proton testing benchmark. NB: 
negative binomial. ZIP: zero-inflated Poisson. ZINB: zero-inflated negative binomial. 
Poi_BF: GLM using Poisson distribution, Bayes factor approach used in chapter 2.   Poisson NB ZIP ZINB Poi_BF VarScan2 
Recall 0.98 0.89 0.95 0.90 0.96 0.83 
Precision 0.25 0.62 0.54 0.71 0.49 0.53 
F1 Score 0.40 0.73 0.69 0.79 0.65 0.65 
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Figure 11 Performance by allele frequency Ion Proton testing benchmark. NB: negative 
binomial. ZIP: zero-inflated Poisson. ZINB: zero-inflated negative binomial. Poi_BF: 
position specific error model using Poisson distribution, with variant identification method 
being the Bayes factor approach used in chapter 2. 
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4.4 Discussion 
The PSEM model aims to predict the position specific error rates associated with 
various genomic sequence contexts, under which the specific sequencing technology is 
prone to error. Based on publications evaluating features associated with sequencing 
errors and experiences from our previous effort, 9 types of significant features are 
considered. With the features fixed, using GLM, we evaluated the appropriateness of 
distributions with different mean – variance relationships and the ability to consider zero-
inflation. Consistent with the computational tool EdgeR [152] for RNA-Seq data, we 
found the ability to model over-dispersion by negative binomial distribution necessary for 
DNA-Seq data as well. Additionally, for DNA-Seq error read counts modeling, zero-
inflation is also a key factor for accurate prediction and inference. The much-elevated F1 
score for 0.5% allele frequency SNVs as well as the highest overall performance by 
ZINB GLM highlighted the importance of choosing suitable statistical models. In addition, 
comparing different variant identification methods, we can see with the appropriate 
distribution, we can use a simple hypothesis-testing approach without requiring 
additional parameters required by Bayes factor, yet still can achieve a higher 
performance. Moreover, comparing with VarScan2, which conducts the Fisher’s exact 
test for each targeted location on paired normal-tumor sequencing data, the significance 
of applying the correct reference error model is exemplified by higher recalls as well as 
precisions for 0.5% and 1% frequency SNVs. In theory, for low frequency SNV loci, 
VarScan2 treated the sequencing reads with non-reference bases from normal as the 
background error, which is essentially point estimation based on one location. Whereas 
PSEM collectively considers all loci with similar context features and thus is able to 
generate more accurate error estimation. 
The current GLM-based PSEM framework only considers 9 types of genome 
sequence context features. To further improve the performances, more informative 
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features associated with sequencing errors should be included and tested. In addition, 
from the modeling aspect, exploration of the potential to further increase the 
performances by applying more sophisticated computational models are desired. When 
applying the position specific error model on sequencing platforms different from Ion 
Proton, new features related to the underlying biochemistry might be added. Thus, to 
better understand its generalizability and adaptiveness in the features used, tests on 
other sequencing technologies, such as Illumina, SOLiD and Complete Genomics, are 
necessary. Except for the sequencing platform effect, the effects of other steps in the 
sequencing library preparation should also be considered, for example the target capture 
assay. Since the capture assay for the Ion Proton benchmarks is amplicon-based, thus 
the reads from the same amplicon are supposed to have the same start and end 
locations. However, hybridization-based approach tends to generate reads with different 
start and end location, therefore, it should be tested to compare the performance profiles 
with amplicon-based approached to see if such a difference may impact the position 
specific error modeling.  
Differentiating low frequency SNVs from sequencing artifacts is the key for 
identifying SNVs at frequencies close to sequencing error rates. Our PSEM approach 
tried to push the limit toward the sequencing error rates. Based on the analyses on 
benchmarks from standard sequencing protocols and the given sequencing depth, we 
speculate the detection limit is around 0.5% on the regions covering all exons of hundred 
of genes, with a total size up to millions of bases. However, with high accuracy 
sequencing protocols, such as duplex sequencing [64] and ultra-deep target enrichment 
assay [97], the researchers reported identification of SNVs around 0.1% on a single 
gene scale. For the future direction, it is worthwhile to test whether we can push the 
detection limit below 0.5% or even 0.1% by coupling the improved experimental 
protocols with our position specific error modeling. 
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Chapter 5. Statistical Modeling for Illumina MiSeq Platform Genomic Sequence 
Context Dependent Error 
5.1 Introduction 
In chapter 4, we explored the possibility of improving the performances of 
position specific error modeling with different statistical distributions. However, same as 
chapter 2, all tests were done on Ion Proton sequencing platform. To understand how 
position specific error modeling behaves on different sequencing platforms, we 
replicated the analysis conducted in chapter 4 on a publically available Illumina MiSeq 
benchmark dataset, published with the low-frequency SNV detection method UDT-Seq 
[15]. The Illumina MiSeq benchmark dataset was chosen for several considerations. 
First, different from the semiconductor based sequencing utilized by Ion Proton 
sequencers; Illumina sequencing platforms used optical system based sequencing by 
synthesis (SBS). This difference enables us to check whether generalized linear model 
based position specific error model can adapt to sequencing platforms based on 
completely different biochemistries. Second, similar to the Ion Proton benchmarks, the 
amplicon based target capture assay was also used by the Illumina MiSeq benchmark 
dataset. Thus we have one less major complication in interpreting the differences. Third, 
the lowest targeted frequency for Illumina MiSeq benchmark is 1%, thus allowing us to 
characterize the effect of different distributions on low-frequency range. 
With the Illumina MiSeq benchmark data set, we wanted to examine whether the 
generalized linear model can be utilized and if so, whether there are any differences in 
terms of the contribution of different sequence context features. For this purpose, we 
controlled the sequence context features to be the same as the ones used in Ion Proton 
benchmarks. In addition, whether the most appropriate statistical distribution remains to 
be zero-inflated negative binomial distribution. 
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5.2 Materials and Methods 
5.2.1 Illumina MiSeq Benchmark Dataset Overview 
The design details can be found in the UDT-Seq paper [15]. Briefly, the length of 
targeted regions for Illumina MiSeq datasets is 23.2 kb, covered by 158 amplicons with 
about 200-nucleotide long. The amplification was done with microdroplet PCR [153]. 
This Illumina MiSeq benchmark data were generated by mixing 4 individuals at 4 
different percentages and then permuted the mixing percentage assignment 4 times to 
generate 4 calibration datasets – CAL_A, CAL_B, CAL_C and CAL_D, details shown in 
Table 13. Sequencing was done with Illumina MiSeq platform, and the read is 151-
nucleotide long. The raw reads were downloaded from NCBI Short Read Archive [154, 
155] (SRP009487.1) and processed as the paper described. Reads with mapping quality 
less than 30 were filtered out. 
For the choice of Illumina MiSeq training and testing benchmarks, since the 4 
calibration data sets were generated with the same procedures, without loss of 
generality, we used CAL_A as training benchmark and treated the others as testing 
benchmark. Also, different from Ion Proton benchmarks, these benchmarks are similar to 
the tumor only or pooled sequencing samples. Thus the all identified candidate SNVs 
were used in the performance evaluation. 
 
5.2.2 Generalized Linear Models and Variant Identification 
To test how different sequencing platforms impact the generalized linear model 
fitting, the same sequence context features used in chapter 4 were also used on Illumina 
MiSeq data. The details of the 9 genomic sequence contexts considered in generalized 
linear models were summarized in Table 2. The same 4 statistical distributions were 
fitted: Poisson, zero-inflated Poisson, negative binomial, and zero-inflated negative 
binomial. In addition, the same hypothesis testing based variant identification testing in 
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chapter 4 was also used here, requiring Benjamini–Hochberg procedure corrected p 
values from both strands to be less than 0.01.  
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Table 13 Illumina MiSeq benchmark design.  
ID CAL_A CAL_B CAL_C CAL_D 
NA12156 1% 5% 20% 74% 
NA12878 5% 20% 74% 1% 
NA18507 20% 74% 1% 5% 
NA19240 74% 1% 5% 20% 
85 
5.2.3 Performance Evaluation Measurements 
Precision, recall and F1 score were used for performance evaluation. For 
Illumina MiSeq dataset, filter 2 used by UDT-Seq [15] was applied which requires >= 
0.2% frequency for alternative bases. However, the other filters were not used, including 
filter 1 removing positions within primers, filter 3 position in the read, filter 4 depth strand 
bias, filter 5 depth discrepancies between training and testing samples, filter 6 binomial 
test p values on the significance of different from sequencing error rates and filter 7 local 
sequencing context based filters. We relied on the PSEM framework to properly address 
sequence contexts and depth related problems. 
 
5.3 Results 
In the result section, we first show the comparison of the appropriateness of the 4 
candidate distributions. Then we compared the coefficients in generalized linear models 
on Illumina MiSeq with those from Ion Proton to look for the impact of different 
sequencing benchmarks. Next, to set the stage for understanding the performance 
differences, we first compared the differences in designed allele frequency composition 
as well as sequencing depth between the Illumina MiSeq and Ion Proton testing 
benchmarks. We concluded by evaluating the candidate variant identification 
performances and the comparison between position specific error model and UDT-Seq. 
 
5.3.1 Comparing the Goodness-of-Fit of Different Distributions 
To evaluate the generalizability and adaptiveness of the generalized linear model 
based position specific error modeling, the same modeling strategies were applied to the 
Illumina MiSeq sequencing data sets. Similar to the analysis on Ion Proton data set, 
paired Vuong’s non-nested hypothesis tests were conducted on the 4 candidate 
distributions, with details summarized in Table 14. The tests show the most appropriate 
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distribution is still zero-inflated negative binomial. However, for the negative binomial 
(NB) (model 1) and zero-inflated Poisson (ZIP) (model 2) comparison, the BIC-corrected 
Vuong z-statistic is -0.47 resulting in p value = 0.318. Therefore the goodness-of-fit for 
these two distributions on MiSeq dataset are not significantly different.  
 
5.3.2 Comparing Generalized Linear Models on Different Sequencing Platforms 
Despite similar statistical modeling schema can be readily generalized to Illumina 
MiSeq data set, Illumina MiSeq and Ion Proton sequencers differ significantly in terms of 
sequencing chemistry. The former is based on sequencing-by-synthesis (SBS) that 
relies on high-resolution optic systems, whereas the latter is based on Ion 
semiconductor sequencing where no modified nucleotides or optics are required. The 
differences in sequencing mechanisms make Ion Proton sequencers run faster but are 
prone to homopolymer related errors. Comparing the negative binomial generalized 
linear model regression coefficients on both datasets (Table 15), homopolymer related 
features significant in Ion Proton data set regression are either insignificant (hmer_len, 
hmer_dist) or show opposite effect (hmer_op, hmer_den) on the error rate.  
 
5.3.3 Benchmarks Comparison 
Comparing the Illumina MiSeq testing benchmark with the Ion Proton testing 
benchmark, Ion Proton dataset contains a total of 1557 somatic SNVs while Illumina 
MiSeq dataset contains 514 SNVs, in which 175 SNVs are unique. More importantly, Ion 
Proton benchmark was designed to comprehensively characterize the SNV caller 
performance on close to sequencing error allele frequencies, thus it is enriched with 
SNVs of <= 3% allele frequencies, with 0.5% as the lowest targeted frequency. Plotting 
the cumulative percentages of SNV numbers at different allele frequencies (Figure 12) 
from the two test benchmarks, it is clear the major components of Ion Proton test 
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benchmark SNV allele frequencies are at 0.5%, 1%, 2% to 5%, followed by continuous 
frequencies until 46%, the maximum somatic SNV frequency designed in the dataset. 
Whereas Illumina MiSeq testing benchmark set is enriched with SNVs at the 4 discrete 
allele frequency levels same as the design. 
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Table 14 Vuong’s non-nested test on 4 distributions applied to Illumina MiSeq 
training data.  
 
Model 1 
 
Model 2 
Vuong z-statistic 
BIC-corrected 
 
Hypothesis 
 
P value 
Poisson NB -23.38 model2 > model1 < 2.22e-16 
Poisson ZIP -21.30 model2 > model1 < 2.22e-16 
NB ZIP -0.47 model2 < model1 0.31796 
ZIP ZINB -20.22 model2 > model1 < 2.22e-16 
NB ZINB -17.44 model2 > model1 < 2.22e-16 
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Table 15 Negative binomial GLM coefficients for Ion Proton and Illumina MiSeq 
training datasets.  
Ion Proton Illumina MiSeq 
 
Parameter 
 
Estimate 
Standard 
Error 
 
P value 
 
Estimate 
Standard 
Error 
 
P value 
(Intercept) -10.9331 0.0105 < 2e-16 -1.0700 0.0290 < 2e-16 
A → C -0.1516 0.0072 < 2e-16 0.6922 0.0220 < 2e-16 
A → G 1.5093 0.0060 < 2e-16 2.6550 0.0190 < 2e-16 
A → T -0.0352 0.0072 < 2e-16 -0.2219 0.0270 4.26e-16 
C → A -0.1073 0.0075 < 2e-16 -0.3068 0.0290 < 2e-16 
C → G -0.3362 0.0080 < 2e-16 -0.9909 0.0360 < 2e-16 
C → T 1.3287 0.0062 < 2e-16 1.8840 0.0200 < 2e-16 
G → A 1.2600 0.0062 < 2e-16 1.7870 0.0200 < 2e-16 
G → C -0.2030 0.0077 < 2e-16 -0.7178 0.0330 < 2e-16 
G → T -0.1705 0.0075 < 2e-16 -0.7540 0.0360 < 2e-16 
T → A 0.0445 0.0071 < 2e-16 -0.2594 0.0270 < 2e-16 
T → C 1.5362 0.0059 < 2e-16 2.7120 0.0190 < 2e-16 
up base A 0.1046 0.0037 < 2e-16 0.1640 0.0100 < 2e-16 
up base C 0.2316 0.0038 < 2e-16 0.4087 0.0100 < 2e-16 
up base G 0.3288 0.0037 < 2e-16 0.5110 0.0100 < 2e-16 
down base A -0.0908 0.0037 < 2e-16 -0.2120 0.0100 < 2e-16 
down base C 0.3356 0.0036 < 2e-16 0.3462 0.0090 < 2e-16 
down base G 0.1748 0.0037 < 2e-16 0.2600 0.0090 < 2e-16 
GC 0.0058 0.0001 < 2e-16 0.0099 0.0003 < 2e-16 
hmer_den 0.2994 0.0136 < 2e-16 -0.0798 0.0360 0.028 
hmer_op 0.3313 0.0037 < 2e-16 -0.1430 0.0100 < 2e-16 
hmer_dist -0.0137 0.0004 < 2e-16 -0.0009 0.0010 0.4 
hmer_len 0.0790 0.0012 < 2e-16 0.0018 0.0030   0.569 
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Figure 12 Allele frequency composition of Ion Proton and Illumina MiSeq testing 
benchmark SNVs. 
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Except for allele frequency composition, sequencing depth is also a crucial factor 
affecting the performances of the SNV callers, especially at the low-frequency range. 
The average depth for Ion Proton sequencing testing benchmark is about 4000x and 
about 1500x for MiSeq. In addition, despite the amplicon-based capture assay was 
applied on benchmark datasets from both technologies, the evenness of the depth 
across the targeted regions is different. When comparing the depth on known testing 
benchmark SNV loci of two technologies (Figure 13), the depth distribution for Ion Proton 
is skewed while the distribution profile for Illumina MiSeq data displays a bell shape. For 
Ion Proton testing benchmark SNV loci, 85.4% of all loci have a depth no less than 
1000x, while 98.1% for Illumina MiSeq. Further, the average depth at SNV loci from both 
benchmarks are around 3000x, despite the much higher overall depth in Ion Proton 
benchmark. Thus, we speculate lowered recall for some Ion Proton benchmark SNVs, 
particularly for the ≤ 1% ones, the identifiable power of which are more sensitive to the 
depth and read count number sampling variances. 
 
5.3.4 Performance Evaluation on Illumina MiSeq Testing Benchmark 
To evaluate whether the differences in generalized linear model coefficients 
affect the performance profiles on various allele frequencies, we applied the 4 
generalized linear models trained on CAL_A to the testing benchmark dataset combining 
CAL_B, CAL_C and CAL_D. And then we conducted the recall, precision and F1 score 
analyses by allele frequency on the combined dataset. As shown in Figure 14, similar to 
the Ion Proton data set, SNVs of lower allele frequencies are more difficult to identify. 
However, when comparing the performances of zero-inflated Poisson with negative 
binomial GLM on 0.5% ~ 1% allele frequency, different from Ion Proton dataset, negative 
binomial demonstrated a much higher F1 score compared with zero-inflated Poisson. A 
closer look at the performance profiles shows the noticeable drop in recall comparing 
92 
negative binomial with zero-inflated Poisson in Ion Proton is absent in MiSeq data. 
Examination on the benchmark SNVs missed by negative binomial but recovered by 
zero-inflated Poisson showed lower depth for the missed ones. Therefore the absent of 
recall drop in MiSeq is due to its relatively even depth contrast to the Ion Proton dataset 
(Figure 13). For SNVs with > 1% allele frequency, the F1 scores are all greater than 0.9 
and clustered together for all distributions. 
Comparing with the results from UDT-Seq [15], which reported approximately 
90% recall and >95% precision (no specific number was given, the precision was 
inferred by the precision for the other data UDT-Seq tested - Illumina GAII benchmark 
data at 1500x depth), zero-inflated negative binomial generalized linear model 
demonstrates higher overall recall (95.1%) and high precision (93.4%). 
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Figure 13 SNV loci depth distribution by allele frequency for Ion Proton and Illumina 
MiSeq. The dashed lines show the 3000x depth. 
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Figure 14 Performance by allele frequency summary on Illumina MiSeq testing 
benchmark. 
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5.4 Discussion 
The evaluation of position specific error modeling on Illumina MiSeq dataset 
showed the generalizability of the position specific error modeling framework as well as 
its adaptiveness to different technologies. The position specific error modeling 
framework adapts to training data from different technologies by adjusting the 
coefficients in fitted generalized linear models. Moreover, except for the established 
importance of choosing appropriate statistical model, the sequencing depth evenness is 
also an important factor affecting low-frequency SNVs calling performances.  
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Chapter 6. Conclusions and Future Directions 
The overall focus of this dissertation project is to develop a computational 
framework to sensitively and specifically detect low frequency SNVs from NGS based 
DNA sequencing data. The major difficulty of this task is to characterize artifacts in 
sequencing data and distinguish them from the low-frequency SNVs, which may present 
at a similar level as the artifacts. We sought to tackle this problem by modeling the end 
result of all sources of errors originated from various steps of the NGS experiment 
workflow, to effectively distinguish errors from low-frequency SNVs computationally. 
Particularly, the position specific error model characterizes the genomic sequence 
contexts-dependent error tendencies of the sequencers and thus determines the 
detection limits for sensitive low-frequency SNV identification. Machine-learning-based 
recalibration further considers sequencing quality features unique to each candidate 
SNV locus and boosts the specificity. Training data containing comprehensive low-
frequency SNVs are needed for the computational framework to build a representative 
and robust model. Since different sequencing pipelines (generally including library 
preparation, amplification and sequencing instrument) have differential error profiles 
[156], it is a challenging task to develop a model that adapts to different sequencing 
pipelines. The configuration of RareVar computational framework enables it to adjust to 
different pipelines when fed with data from the target pipeline. This benchmark 
generation step is an integral part of RareVar framework when applied to data from a 
previously uncharacterized sequencing pipeline. By performance comparison with 
existing methods, we confirmed the effectiveness of RareVar in sensitively and reliably 
detecting low-frequency SNVs, with the advantage most evident in 0.5% ~ 3% allele 
frequencies. 
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 Generating a benchmark dataset suitable for comprehensive low-frequency 
SNVs detection evaluation is a nontrivial task [82]. By sequencing the DNA sample 
mixture of multiple individuals previously genotyped by 1000 Genomes Project, the 
benchmark data not only contain a large number of known SNVs, but also preserve the 
bona fide sequencer error profiles likely lost by simulation-based approaches [76-80, 
82]. Also, contrast to other deep sequencing efforts for low-frequency SNV detection, 
which targeted less than 50kb regions, Ion AmpliSeq Comprehensive cancer panel 
targets about 1.7 million bases, encompassing half of the known oncogenes and tumor 
suppressor genes. The invariant loci of the targeted regions provide comprehensive 
training data for the position specific error model, which facilitate the building of unbiased 
error profile models. On the other hand, the large number of variant loci, which were 
enriched with low-frequency SNVs by our design, allows the machine-learning-based 
recalibration to delineate the sophisticated boundaries between true low-frequency 
SNVs and sequencing artifacts. 
 The ability to capture the differential context-dependent error rates is the key for 
sensitive detection of close to error rate SNVs. We applied Poisson-distributed 
generalized linear model to integrate 9 sequence context features for position specific 
error rates modeling. Comparing with existing error rate modeling approaches, our 
generalized linear model framework modeled the combinatorial effects of more features 
than tabulation-based method [15], likelihood ratio based method [23, 72] and recursive 
sequencing error probability modeling [75], in which the latter two methods mainly rely 
on base quality feature. The position specific error model allows finer differentiation of 
biased sequencing error rates. Besides, the scalability of the generalized linear model 
removes the need to make unrealistic assumptions, such as the equal substitution error 
rates at each locus assumed by the likelihood ratio method. In the precision and recall 
comparisons with other tools, the position specific error model recovered the most 
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known SNVs, with the advantage more evident at lower allele frequency ranges. In 
addition, its precision is comparable with VarScan2, thus selecting a high quality 
candidate SNV set for further refinement. 
 The machine-learning-based candidate recalibration step in RareVar considers 
sequencing quality features to refine the candidates. This strategy was also used in 
GATK [65]. However, the recalibration in our framework is tailored to low-frequency SNV 
detection. First, comparing to the dbSNP germline SNVs used as positive set in GATK, 
the true SNVs in our designed benchmark covered a wide range of continuous 
frequencies and more importantly, enriched at low frequency ranges. Thus it is a suitable 
training data set for modeling features of cancer somatic mutations and pooled 
sequencing variants, especially at the lower frequencies. Second, instead of trying to 
only capture the characteristics of true SNVs in GATK, we had both true SNVs defined 
by the benchmark data as well as the false positive SNVs generated by position specific 
error model step, allowing us to distinguish the two types. Moreover, the candidate SNVs 
derived after position specific error modeling are enriched with true SNVs, thus they 
constitute an ideal training set to optimize the classification boundaries for higher 
sensitivity and specificities. We showed the effectiveness of the machine-learning-based 
recalibration in boosting the precision as well as preserving high recall by comparing it 
with the position specific error model as well as other existing tools. The aforementioned 
advantages in framework design were highlighted by the highest precision increase at 
0.5% and 1% frequency ranges. 
 From benchmark design, position specific error model to machine-learning-based 
candidate recalibration, these major components of RareVar framework operate 
synergistically to optimize the performance on low-frequency SNV detection. Enriched 
low-frequency SNV benchmark enables supervised learning for the downstream 
components to effectively distinguish low-frequency SNVs from sequencing artifacts. 
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The strategy of using benchmark data also enables adapting to different sequencing 
platforms by feeding downstream components with training data from the platform of 
interest. The value of tailoring the model toward the platform used is pinpointed when 
RareVar and TVC, the two methods more tailored to Ion Torrent sequencing technology, 
significantly outperformed popular methods previously tailored for Illumina sequencing 
technology.  Computational components position specific error model and machine-
learning-based candidate recalibration characterize the context-dependent systematic 
sequencer error tendency and locus-specific sequencing qualities, respectively. 
Moreover, both the generalized linear model and machine learning algorithm random 
forest are capable of incorporating more features, thus guarantees extensibility of 
RareVar. 
 Next-generation sequencing error data are in essence count data. In chapter 3, 
we showed that the effectiveness of different statistical distributions on position specific 
error modeling was different. By keeping the sequence context features the same, 
observed differences in performance were due to differential goodness-of-fit for the 
tested distributions. Similar to RNA sequencing differential expression analysis, negative 
binomial distribution showed statistically significant better goodness-of-fit than Poisson 
distribution, due to its extra parameter in dealing with overdispersion of next-generation 
sequencing count data [152, 157]. Unique to sequencing error count data is the large 
percentage of zeros, or zero-inflation, since the average error rate is only 0.1% to 1% for 
most platforms. The zero-inflated counterparts of both Poisson and negative binomial 
distributions fit statistically better, as shown by Vuong’s test. Zero-inflated negative 
binomial distribution statistically fit the sequencing error data the best. Such an 
advantage was also reflected in higher overall performance in detecting SNVs, 
especially at 0.5% and 1% frequencies, demonstrating the practical value of applying 
statistically fitter distributions. Furthermore, both Ion Proton and Illumina MiSeq data 
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supported this conclusion. Zero-inflated negative binomial distribution captures generic 
features of the next-generation sequencing error count data. 
 The adaptiveness of generalized linear model for position specific error modeling 
was demonstrated in chapter3. When fed with sequencing data from different platforms, 
the model adjusted to different platforms by learning different coefficients. Comparing 
the fitted coefficients for Ion Proton and Illumina MiSeq data, most homopolymer related 
features that explain Ion Proton sequencing errors were no longer significant in Illumina 
MiSeq model. Given the successful application of machine-learning-based recalibration 
in GATK, which is broadly applied on Illumina sequencing data, as well as its 
effectiveness in Ion Proton dataset demonstrated in chapter 2, both computational 
components in RareVar are proved to be adaptive to different sequencing platforms. 
 Low-frequency SNVs detection is the key component in identifying mutational 
drift and/or enrichment in breast tumors. By comparing the SNVs in primary tumor tissue 
with the ones identified in cultured reprogrammed tumor cells, low-prevalent and 
potentially actionable SNVs missed by sequencing bulk tumor could be recovered. 
Applying RareVar on these data, we identified both known and novel somatic mutations 
enriched in reprogrammed tumor cells. Further experimental validation and functional 
study is on going. 
 The future directions for RareVar framework refinement are improving the 
position specific error model and the machine-learning-based recalibration. For the 
position specific error model, identifying and incorporating more features informative of 
sequencer error tendencies are desired. Also, the benefit of considering interactions 
between features in addition to combinatorial effects is worth exploring. Similarly, 
designing more sequencing quality features as well as selecting the most informative 
subset of features for distinguishing true SNVs from sequencing artifacts are the major 
concerns for the machine-learning-based recalibration.  
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 In summary, we developed an adaptive and flexible framework for high 
performance low-frequency SNV detection. Such a method extends the application 
territory of sequencing based strategies, and also have the potential to greatly facilitate 
cancer and population genetics researches as well as clinical applications such as 
cancer early diagnosis, metastasis monitoring and relapse identification.   
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